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Regulatory Interaction of the Class III PI3 Kinase Complex and p53 
 
Abstract 
 
  Autophagy is a catabolic pathway utilized by cells to maintain homeostasis. 
Dysregulation of this pathway often leads to various diseases, such as cancers and 
neurodegeneration. Therefore, autophagy must be tightly regulated by the extracellular 
environment or signaling pathways. The class III PI3 kinase complex, a lipid kinase complex 
functioning in converting phosphatidylinositol to phosphatidylinositol-3-phosphate, is a key 
regulator of autophagy that functions as a signaling hub where multiple regulatory signals 
converge. 
  Here, we demonstrate that the class III PI3 kinase complex is negatively regulated by 
cyclin-dependent kinases (Cdks). The catalytic subunit of the kinase complex, Vps34, is 
phosphorylated by Cdk1 in mitotic cells and by Cdk5 in postmitotic cells. Phosphorylation on 
Vps34 results in its dissociation from a regulatory subunit Beclin 1, leading to decreased lipid 
kinase activity. As a result, autophagy is inhibited in dividing cells and postmitotic neuronal cells 
with elevated Cdk5 activity. Since dysfunction of autophagy has been shown to be implicated in 
cancers and neurodegeneration, which are characterized by abnormal activity of Cdk1 and 
Cdk5, respectively, our study provides a mechanism by which autophagy is modulated in those 
diseases.   iv 
  To further discover the regulatory mechanisms of autophagy, we used a novel 
autophagy inhibitor, spautin-1, identified in a small molecule screening. Spautin-1 inhibits 
autophagy by inhibiting Usp10/Usp13, which deubiquitinate and stabilize the class III PI3 kinase 
complex. Interestingly, Usp10/Usp13 are also stabilized by the class III PI3 kinase complex, 
suggesting that they are reciprocally regulated. These results led us to the observation that p53, 
a substrate of Usp10 is regulated by the class III PI3 kinase complex and spautin-1. We also 
report that A70, a more potent derivative of spautin-1, leads to the degradation of mutant p53 
through the chaperone-mediated autophagy, whereas the wild-type p53 is degraded by the 
ubiquitin-proteasome system. Our study demonstrates an important regulatory interaction 
between the class III PI3 kinase complex and p53, suggesting a novel tumor suppressive 
function of the class III PI3 kinase complex. 
   v 
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Chapter 1 
 
Introduction 
   2 
Autophagy and Its Significance 
Overview: Autophagy 
Autophagy is a catabolic pathway utilized by cells to recycle intracellular materials in 
order to generate energy and building blocks for macromolecules. This pathway is well 
conserved throughout the eukaryotes ranging from yeast to human. There are three different 
types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy 
(Figure 1.1A-C). In macroautophagy, double membrane structures called autophagosomes 
engulf some portion of cytoplasm that include cellular components, and deliver them to the 
lysosomes for degradation. Lysosomes can also engulf small components of the cytosol through 
the invagination of the membrane, which is called microautophagy (Li et al., 2012). Chaperone-
mediated autophagy is distinct from the others in that the substrates of this pathway are 
escorted to the lysosomes with the help of chaperone protein Hsc70 (heat shock cognate 
protein 70), and then bind to the lysosomal membrane protein Lamp-2A (lysosomal-associated 
membrane protein 2A) to translocate (Orenstein and Cuervo, 2010). These pathways share the 
lysosomal degradation of cellular components in common, whereas the protein machinery 
involved in the delivery of the components to the lysosomes differs. Among these pathways, 
macroautophagy (hereafter simply referred to as autophagy) has been most intensively studied 
thus far.  
Although autophagy has been discovered as a survival mechanism under starvation 
conditions, it plays a crucial role to maintain homeostasis, especially in higher eukaryotes 
(Mizushima et al., 2008). Protein aggregates that can no longer be degraded by proteasomes, 
damaged organelles, and intracellular pathogens can be cleared by autophagy. Therefore,    3 
 
 
 
 
Figure 1.1. Three Different Types of Autophagy  
(A) In macroautophagy, bulky cytoplasmic components such as cellular organelles can be 
enclosed by a double membrane structure. After the membrane is elongated and closed, the 
outer membrane of the autophagosome is fused with lysosome, and the cargoes of the 
autophagosome including the inner membrane are degraded by the lysosomal hydrolases. 
(B) In microautophagy, lysosomal membrane is invaginated, capturing a small portion of cytosol 
that mostly consists of soluble components. Engulfed vesicle is then degraded by lysosomal 
hydrolases. 
(C) In chaperone-mediated autophagy, substrates with specific targeting sequence are 
recognized by Hsc70 and co-chaperones. The chaperones then bind to Lamp-2A to mediate the 
translocation of unfolded substrates into the lysosome. 
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Figure 1.1 (Continued). 
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dysregulation of this pathway may lead to the accumulation of pathogenic materials in the cells 
and cause various diseases. For example, impairment of basal level autophagy in the brain 
results in the accumulation of protein aggregates and neurodegeneration in mice (Hara et al., 
2006; Komatsu et al., 2006). Drosophila mutants that carry autophagy deficiency show 
increased susceptibility to the infection by certain pathogens (Shelly et al., 2009; Yano et al., 
2008). Moreover, autophagy is required for proper differentiation and development process in 
multicellular organisms (Mizushima and Levine, 2010). 
However, over-activation of autophagy may lead to deleterious consequences. Excess 
autophagy has been shown to induce muscle wasting and implicated in muscle atrophy 
(Mammucari et al., 2007; Zhao et al., 2007). Moreover, autophagosomes can be used for some 
pathogens such as hepatitis B virus and coronaviruses to replicate (Sir et al., 2010; Reggiori et 
al., 2010). Therefore, understanding the mechanism of autophagy is important for developing 
methods to modulate autophagy for therapeutic purposes. 
 
Autophagosome Formation 
The mechanism of autophagy can be divided into different stages: nucleation, 
elongation, closure, and recycling (Levine and Yuan, 2005; Codogno et al., 2011). Each stage is 
carried out by different sets of genes. The genes involved in autophagy have first been 
identified in autophagy-deficient yeast mutants, and they are highly conserved in mammals 
(Tsukada and Ohsumi, 1993). In mammals, mTOR (mammalian target of rapamycin) and AMPK 
(AMP-activated protein kinase) are regulated by the nutrients around the cell, and 
phosphorylates ULK1 (unc-51-like kinase 1), which is a positive regulator of autophagy (Kim et   6 
al., 2011). When the cells are under nutrients-deprived conditions, AMPK is activated and 
phosphorylates Ser317/Ser777 on ULK1 to activate it. In contrast, under rich nutrition, mTOR is 
activated and phosphorylates Ser757 on ULK1 to inactivate it. Active mTOR also disrupts the 
regulation of ULK1 by AMPK. This regulation describes how autophagy can be triggered by 
orchestrated nutrition-dependent signaling pathways. 
Upon induction of autophagy, autophagosomal membrane, derived from various 
intracellular membrane sources, forms a structure called phagophore. Endoplasmic reticulum 
(ER), Golgi, mitochondria, and even plasma membranes have been reported as membrane 
donors for autophagosome, although phagophore formation takes place at the close distance 
from ER (Mizushima et al., 2011). Activated ULK1, together with its binding partners such as 
Atg13, FIP200 (focal adhesion kinase family interacting protein of 200kDa), and Atg101, 
translocates to ER, and positively regulates the class III phosphatidylinositol-3-kinase (PI3 
kinase) complex (Ganley et al., 2009; Jung et al., 2009; Chang and Neufeld, 2009; Hosokawa et 
al., 2009). Conversion of PI to PI3P is a key event in the nucleation step of autophagy, and PI3P 
recruits DFCP1 (double FYVE-containing protein 1) and WIPI (WD repeat domain 
phosphoinositide-interacting protein) proteins which contain domains specifically recognizing 
PI3P over other phosphoinositides to promote the phagophore formation (Matsunaga et al., 
2010; Polson et al., 2010). 
Once the autophagosome is nucleated, vesicle elongation is mediated by the ubiquitin-
like conjugation system. LC3 (microtubule-associated protein 1 light chain 3) and Atg12 are 
ubiquitin-like proteins conjugated to E1-like Atg7 and transferred to E2-like Atg10 and Atg3, 
respectively. Atg12 is then conjugated to the substrate, Atg5, which is bound to Atg16L1 to   7 
form an 800kDa oligomeric complex. The complex functions as an E3-like enzyme to link LC3 
protein to phosphatidylethanolamine (PE), which is used as a marker of autophagy (Noda et al, 
2008). Lipidated LC3 (LC3-II) is separatable from cytosolic LC3 (LC3-I) by SDS-PAGE. Moreover, 
LC3-II appears as puncta under fluorescence microscope, whereas LC3-I is diffused in the 
cytosol. The mammalian paralogues of LC3, such as GABARAP (g-aminobutyric acid receptor-
associated protein) isoforms, are expressed as precursors, which require Atg4 cysteine protease 
for activation (Kabeya et al., 2004). Autophagosomes are decorated with the LC3 family both on 
inner and outer membrane, and inhibition of LC3 lipidation by knockout of any conjugating 
enzyme or expressing dominant-negative form of Atg4 leads to the accumulation of abnormal 
phagophores, suggesting that LC3 lipidation is a crucial step for the expansion and closure of 
the autophagosome (Fujita et al., 2008). Moreover, LC3 binds to the adaptor proteins that 
specifically escort cargoes to the autophagosome. Among the adaptors, p62/SQSTM1 
(sequestosome 1) and NBR1 (neighbor of BRCA1 gene 1) have the ubiquitin-associated domain 
that allows the proteins to recognize ubiquitinated species and target them to the 
autophagosome (Lamark et al., 2009; Kirkin et al., 2009). Nix (also known as BNIP3L) mediates 
autophagic degradation of mitochondria by physically linking the mitochondria to GABARAP 
(Novak et al., 2010; Schwarten et al., 2009). The presence of the adaptors is thought to 
facilitate selective autophagic degradation of polyubiquitinated protein aggregates and 
damaged organelles over normal cytoplasmic constituents. 
After the closed autophagosome is formed, the outer membrane of autophagosome is 
fused with the lysosome to form autolysosome. Then, lysosomal hydrolases, such as proteases 
and nucleases, degrade the cargoes inside the autophagosome as well as the inner membrane.   8 
At the termination step of autophagy, lysosomal membrane generates small tubules and 
vesicles, which in turn produce new lysosomes (Yu et al., 2010). This is an important step to 
maintain lysosomal homeostasis. 
 
Class III PI3 Kinase Complexes 
The class III PI3 kinase was first discovered in screening of yeast cells defective in 
vacuolar protein sorting and named Vps34 (Herman and Emr, 1990). However, the function of 
Vps34 had not been known until the class I PI3 kinase was identified as a lipid kinase (Hiles et 
al., 1992). The catalytic subunit of class III PI3 kinase is homologous to Vps34, suggesting that 
Vps34 is also a lipid kinase. More importantly, the lipid kinase activity of Vps34 is required for 
its function in vacuolar protein sorting (Schu et al., 2003). Different classes of PI3 kinases have 
different substrate specificities. Vps34 preferentially phosphorylates PI to produce PI3P, 
whereas class I PI3K prefers PI4,5P2 to generate PI3,4,5P3 (Vanhaesebroeck et al., 2001). While 
Vps34 is the sole PI3 kinase in yeast, different classes of PI3 kinases exist in mammalian cells, 
rendering it more difficult to study the function of Vps34 genetically and biochemically. 
Moreover, different kinds of PIPs and lipid phosphatases imply that there will be multiple 
pathways to generate PI3P.  
Vps34 forms different complexes with different partners to be functionally active. In 
yeast, the binding partners of Vps34 determine the functions of the complex, such as 
endosomal sorting and autophagy, and many of the binding partners are conserved in 
mammals (Figure 1.2). Vps15, a membrane anchored regulatory subunit of Vps34 is required 
for the activity of Vps34 (Stack et al., 1995). Although p150 has been identified as a Vps15    9 
 
 
 
 
Figure 1.2. The Class III PI3 Kinase Complex  
In the initiation step, the class III PI3 kinase complex plays a crucial role. Vps34, the catalytic 
subunit of the kinase complex, converts PI, a kind of membrane phospholipids, to PI3P by 
phosphorylating the hydroxyl group on the 3rd carbon position of the inositol ring. This step is 
required to recruit the downstream effectors that specifically bind to the PI3P. For its kinase 
activity, Vps34 requires regulatory subunits, such as Beclin 1, p150, and Atg14L, altogether 
forming the class III PI3 kinase complex. Although there are more known subunits that bind to 
the kinase complex, and multiple complexes with different combination of the subunits exist, 
they are not shown in this figure. 
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Figure 1.2 (Continued). 
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homologue in mammalian cells, its role still remains elusive (Panaretou et al., 1997). p150 is a 
protein kinase with a N-terminal myristoylation consensus sequence. p150 is composed of N-
terminal kinase domain followed by multiple HEAT motifs and WD40 domain repeats which are 
known to be involved in protein interaction. In yeast, the HEAT domains of Vps15 are shown to 
interact with the C-terminal conserved sequence of Vps34 (Budovskaya et al., 2002). However, 
whether this interaction is conserved in mammals is not known. Vps15 seems to play a key role 
in multicellular organisms as well. In flies, Vps15 homologue ird1 is required for removal of 
protein aggregates and antibacterial immunity (Lindmo et al., 2008; Wu et al., 2006). 
Vps30/Atg6, another subunit of Vps34 complex in yeast, is involved in both vesicular 
trafficking and autophagy. Beclin 1, a mammalian homologue of Vps30/Atg6, is a haplo-
insufficient tumor suppressor, which is first identified as a Bcl-2 interacting protein with its BH3 
domain (Liang et al., 1998). Since Beclin 1 interacts with Bcl-2/Bcl-xL, Beclin 1 functions as a 
mediator of crosstalk between apoptosis and autophagy (Levine et al., 2008). Moreover, BH3 
domain of Beclin 1 implies that other BH3 containing proteins can also be involved in autophagy 
as well as apoptosis by outcompeting and liberating Beclin 1. 
In addition to p150 and Beclin 1, other mammalian counterparts of the yeast Vps34 
complex have been identified. Atg14L, a homologue of yeast Atg14, is a positive regulator of 
autophagy, and recognizes the membrane curvature of the phagophore (Fan et al., 2011). 
UVRAG (UV radiation resistance associated gene), a homologue of yeast Vps38, is involved in 
the later step of autophagy and endosomal trafficking. In contrast to yeast, mammals have 
Rubicon, as a negative regulator of autophagy (Itakura et al., 2008; Matsunaga et al., 2009; 
Zhong et al., 2009). Moreover, there are other known regulators of autophagy in human cells   12 
such as Ambra1 (activating molecule in Beclin 1-regulated autophagy) and Bif-1 (bax-interacting 
factor-1), which are also required (Fimia et al., 2007; Takahasi et al., 2007). However, the 
detailed molecular mechanisms by which these subunits contribute to autophagy, and their 
regulation have yet to be studied. 
In Chapter 2, we report that the class III PI3 kinase complex is regulated by the cyclin-
dependent kinases (Cdks). Using quantitative microscopy as well as biochemical studies, we 
demonstrate the regulation of the catalytic subunit Vps34 by two different Cdks, namely Cdk1 
and Cdk5. Since Cdk1 and Cdk5 primarily function in dividing cells and post-mitotic neuronal 
cells, respectively, our work describes how autophagy is regulated in different cell types.  
 
Autophagy and Cell Death 
Although autophagy plays a protective role for cell survival, it has also been known to be 
involved in specialized type of cell death, namely autophagic cell death. Autophagic cell death, 
also known as type II cell death, was first defined by the morphology of various dying cells 
(Clarke, 1990). In many dying cells during development, large portions of cytoplasm are filled 
with double or multiple membrane vesicles. However, autophagy is also induced in other types 
of cell death, such as apoptosis or necrosis, there is growing opinion that meaning of 
autophagic cell death should be narrowed down to indicate cell death caused by autophagy. In 
this case, autophagic cell death is inhibited, when autophagy genes are down-regulated or 
autophagy inhibitors are used. 
Autophagic cell death is thought to happen under defined context in specific cell types 
rather than a general phenomenon, and it is best studied in developing insect cells. For   13 
example, removal of salivary glands during development in flies is inhibited by mutations in 
autophagy genes (Berry and Baehrecke, 2007). Germline cell death during oogenesis in female 
flies is also ablated by similar mutations (Nezis et al., 2009). In mammals, autophagic cell death 
is well understood in mouse fibroblast L929 cells. When caspase-8 is inhibited, autophagy is 
induced to selectively degrade catalase, leading to the accumulation of reactive oxygen species 
(ROS) and cell death (Yu et al., 2004; Yu et al., 2006). Inhibition of autophagy by treatment of 3-
methyladenine (3-MA) that blocks the kinase activity of Vps34 reduces this cell death. 
Consistently, knockdown of autophagy genes leads to similar results. This autophagic cell death 
also involves the secretion of tumor necrosis factor a (TNF), which is dependent on the kinase 
activity of RIPK1 (receptor interacting protein kinase 1) and an E3 ligase EDD (Christofferson et 
al., 2012). However, the mechanism by which death signals such as pan-caspase inhibitor zVAD 
or TNF induce autophagy is still elusive.  
In the Appendix I, I discuss the interaction between RIPK1/EDD complex and the class III 
PI3 kinase complex. Although the detailed mechanism has not been demonstrated, the 
interaction and the E3 ligase activity of EDD on UVRAG, one of the subunits of the class III PI3 
kinase complex, suggest that autophagy is directly regulated by RIPK1/EDD complex rather than 
indirectly induced by metabolic stress which is caused during the cell death pathway. 
 
Autophagy and Cancer 
In cancers, autophagy plays a dual role depending on the stage or the nature of the 
cancers. In some cases, autophagy functions as a tumor suppressive mechanism, especially in 
the early stage of tumorigenesis. As discussed above, autophagy is important for the quality   14 
control of the cells such as removing damaged mitochondria. Under metabolic stress, cells are 
more likely to have defects on the mitochondria, leading to increased levels of ROS which result 
in the modification of proteins and nucleic acids and eventually tumorigenesis. Consistently, 
cells with reduced autophagy are more sensitive to metabolic stress (Karantza-Wadsworth et 
al., 2007). They acquire more DNA damage and genomic instability than normal cells. 
Moreover, autophagy-defective tumor cells have accumulated p62/SQSTM1, which is an 
adaptor for ubiquitinated proteins as well as a substrate for autophagy itself (Mathew et al., 
2009). Surprisingly, p62 has been shown to regulate cell defense mechanism at the 
transcriptional level, which may also be involved in tumorigenesis (Komatsu et al., 2010).  
Consistent with the observation that autophagy protects from tumor formation, many 
of the autophagy genes have been reported as tumor suppressor genes, and they are 
frequently mutated in various types of cancers. Among them, Beclin 1 is most widely studied 
and has been shown to be a haploinsufficient tumor suppressor (Qu et al., 2003; Yue et al., 
2003). It is often monoallelically deleted in some types of human cancers, such as breast and 
ovarian cancers, and Beclin 1 heterozygous mice spontaneously develop tumors. Since the 
deletion of Atg7 only leads to the formation of benign tumors in the liver (Takamura et al., 
2011), the aggressive tumor development as a result of mutation in subunits of the class III PI3 
kinase complex, e.g. the tumor phenotype of Beclin 1 heterozygosity, cannot be explained by 
autophagy deficiency alone. This may suggest that Atg5/Atg7-independent autophagy plays a 
role in tumor suppression, or the subunits of the class III PI3 kinase complex have a function 
totally separate from the PI3 kinase activity (Nishida et al., 2009). Notably, UVRAG is shown to   15 
contribute to chromosomal stability by promoting DNA double strand break repair, as well as 
assisting proper chromosome segregation (Zhao et al., 2012). 
However, once the tumors progress to a certain stage, autophagy can promote the 
survival and resistance of the tumors. Since cancer cells reside in a microenvironment that 
provides cells with limiting nutrients and oxygen, utilization of autophagy to generate energy 
for cell survival is crucial. Moreover, most chemotherapeutic agents specifically target cancer 
cells by inducing cytotoxicity to highly proliferative cells, suggesting that autophagy as a cellular 
defense mechanism may reduce the effect of such treatments. Therefore, inhibition of 
autophagy by using small molecules or knockdown of autophagy genes often causes cancer cell 
death. In tumors with oncogenic Ras, defective autophagy reduces tumorigenicity (Guo et al., 
2011). Similarly, autophagy inhibitors such as chloroquines are being tested for combination 
treatment with currently known anti-cancer drugs (White and DiPaola, 2009). Interestingly, 
autophagy has also been shown to contribute to the aggressiveness of the cancers by 
facilitating metastasis (Fung et al., 2008). Nevertheless, inducing cancer cell death by blocking 
autophagy is not always beneficial because apoptosis-incompetent cells undergo necrotic cell 
death, leading to further proliferative environment by triggering pro-inflammatory responses 
(Degenhardt et al., 2006). 
As discussed above, the effect of autophagy on cancers is dependent on multiple factors 
such as the microenvironment, stage, and genetic background. Thus, autophagy targeting 
therapeutic interventions must be considered carefully, and preceded by the studies to identify 
the nature of the cancers to be treated. 
   16 
Chaperone-mediated Autophagy 
Chaperone-mediated autophagy (CMA) is distinct from other types of autophagy in that 
CMA does not involve membrane invagination. The substrate proteins for CMA are targeted to 
the lysosome directly by binding to the chaperone Hsc70 and co-chaperones through the 
recognition sequences (KFERQ or biochemically related sequences) on the substrates (Chiang et 
al., 1989). This suggests that CMA has the highest selectivity among different types of 
autophagy. Then, the lysosomal membrane protein Lamp-2A binds to the substrates to 
translocate them into the lysosomes where the substrates are degraded (Cuervo and Dice, 
1996). 
CMA has been reported to be activated after prolonged starvation of oxidative stress 
(Cuervo et al., 1995; Kiffin et al., 2004). It is also constitutively active when macroautophagy is 
compromised (Kaushik et al., 2008). More importantly, CMA is implicated in proteotoxicity 
caused by adverse alterations or modifications of proteins. Conversely, excess modifications or 
aggregation of proteins prevent the substrate proteins from being degraded by CMA. For 
example, mutation on -synuclein impairs its degradation by CMA, which at least in part, 
contributes to the pathogenesis in Parkinson’s disease (Cuervo et al., 2004). Interestingly, 
artificial delivery of mutant huntingtin to the lysosomes using CMA ameliorates the disease 
phenotype of Huntington’s disease (Bauer et al., 2010). Notably, the activity of CMA declines 
with age, suggesting that the age-dependent increasing incidence of neurodegenerative 
diseases may be attributed to decreased protein quality control mechanism by CMA (Kiffin et 
al., 2007).   17 
p53 as a Tumor Suppressor 
Function and Regulation of p53 
p53 was identified as a binding protein of simian virus 40 (SV40) large T-antigen in 
mediating the transformation of normal cells to tumors (Lane and Crawford, 1979; Linzer and 
Levine, 1979). For a long time, p53 was believed to be oncogenic due to its elevated expression 
in transformed cells (Sarnow et al., 1982). Consistent with an oncogenic role, several clones of 
p53 actually enhanced tumorigenesis (Eliyahu et al., 1984; Jenkins et al., 1984; Parada et al., 
1984). However, the tumor suppression role of wild-type p53 was revealed after extensive 
molecular biology and genetic studies. Consistently, deletion mutations in p53 gene were found 
in cancers (Baker et al., 1989). Overexpression of wild-type p53 suppressed tumor formation 
induced by other known oncogenes such as Ras and Myc (Eliyahu et al., 1989; Finlay et al., 
1989). Most importantly, loss of p53 in mice results in spontaneous tumor formation, 
suggesting that p53 is a bona fide tumor suppressor (Donehower et al., 1992). 
Extensive studies have demonstrated that p53 functions as a guardian of the genomic 
stability. Under normal conditions, the activity of p53 remains low. However, when the cells are 
under various stresses such as genotoxic stress or oxidative stress, p53 becomes activated and 
mediates multiple stress responses. The most intensively studied function of p53 is as a 
transcription factor with the DNA-binding domain flanked by N-terminal transactivation domain 
and C-terminal regulatory domain. Since p53 was shown to bind to the specific sequence of 
DNA, many target genes have been identified including p21 that is a cyclin-dependent kinase 
inhibitor (Menendez et al., 2009). Notably, many target genes of p53 are involved in cell cycle 
arrest, senescence, and programmed cell death.   18 
The function of p53 is not limited in the nucleus. It also plays an important role in the 
cytoplasm, contributing to it being a tumor suppressor. Interestingly, in addition to activating 
the expression of apoptotic genes, p53 directly regulates the execution of apoptosis in the 
cytoplasm. When p53 is accumulated in the cytosol, it is localized to the mitochondria and 
induces permeabilization of the outer membrane (Mihara et al., 2003). p53 also activates 
proapoptotic proteins that are sequestered by antiapoptotic proteins under normal condition 
(Chipuk et al., 2004). In addition to the proapoptotic functions, cytoplasmic p53 is involved in 
centrosome duplication to ensure proper chromosome segregation. In the absence of p53, 
multiple centrosomes are generated in a single cell cycle, leading to chromosomal instability 
(Fukasawa et al., 1996). 
Decades of studies have demonstrated the mechanisms by which p53 is regulated. p53 
is constitutively ubiquitinated and rapidly degraded through the proteasome under normal 
condition. Although this regulatory mechanism was first shown by viral oncogene, several 
endogenous regulators have also been reported (Scheffner et al., 1993). Among the different 
regulators of p53, Mdm2 (mouse double-minute 2) has been best characterized. Mdm2 gene 
was amplified in a spontaneously transformed cell line, suggesting its oncogenic property 
(Fakharzadeh et al., 1991). Molecular studies has revealed that Mdm2 physically interacts with 
p53 and inhibits its activity (Momand et al., 1992; Oliner et al., 1992). Moreover, this inhibition 
is attributed to the ubiquitination-dependent degradation of p53 due to the function of Mdm2 
as an E3 ligase for p53 (Haupt et al., 1997; Kubbutat et al., 1997; Honda et al., 1997). 
Interestingly, low levels of Mdm2 mediate monoubiquitination of p53 that leads to its nuclear 
export, whereas high levels of Mdm2 promote polyubiquitination and degradation (Li et al.,   19 
2003). Furthermore, the expression of Mdm2 is positively regulated by p53, generating a 
negative feedback loop (Barak et al., 1993; Wu et al., 1993). Therefore, when p53 is activated, 
Mdm2 expression increases to maintain the levels of p53 low after the cell overcomes the 
stress and no longer requires p53. In contrast, Mdm2 regulates p53 by monoubiquitination 
under normal condition. Regulation of p53 by Mdm2 is indispensible for proper embryonic 
development, and loss of Mdm2 results in embryonic lethality that can be rescued by loss of 
p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995). 
In contrast to the low levels of p53 in normal conditions, p53 protein is highly 
accumulated upon genotoxic stress, such as DNA damage induced by UV radiation. This 
accumulation is achieved either by inhibition of ubiquitination or by inducing deubiquitination. 
After DNA damage, the posttranslational modifications on p53 inhibit ubiquitination by Mdm2. 
For example, acetylation on the C-terminal lysine residues of p53 blocks ubiquitination because 
acetylated lysines can no longer serve as substrates for ubiquitination (Li et al., 2002). In the 
same sense, deacetylation of p53 promotes its degradation by Mdm2-mediated ubiquitination 
(Ito et al., 2002). In addition to acetylation, phosphorylation of p53 on its N-terminus also leads 
to the activation by inhibiting the interaction with Mdm2 (Shieh et al., 1997). Moreover, p53 
can be stabilized by deubiquitination, which is mediated by multiple deubiquitinases (DUBs). 
HAUSP (herpes virus-associated ubiquitin specific protease) regulates p53 activity by 
deubiquitinating both p53 and Mdm2 depending on the expression levels (Li et al., 2004). 
Usp10 is activated by DNA damage and stabilize p53 by deubiquitination (Yuan et al., 2010). 
Therefore, the stability and activity of p53 is systematically regulated by coordinated 
modifications and/or removal of modifications.   20 
Regulation of Autophagy by p53 
As a protective mechanism that helps cells deal with different kinds of stress, autophagy 
is regulated by p53. Interestingly, p53 can both activate and suppress autophagy depending on 
its cellular localization and mediators. Many of the genes transcriptionally activated by p53 are 
inducers of autophagy. Among the target genes is ULK1 that is required for autophagy (Gao et 
al., 2011). Upon DNA damage, p53 directly activates the transcription of ULK1, which in part 
mediates p53-dependent DNA damage responses. p53 also negatively regulates mTOR signaling 
pathway, resulting in the activation of autophagy (Feng et al., 2005). Notably, p53-dependent 
transcription of Sestrin1 and Sestrin2 has been reported to activate AMPK (Budanov and Karin, 
2008). Activated AMPK then phosphorylates and activates TSC2 (tuberous sclerosis protein 2) 
that inhibits mTOR. Loss of Sestrin2 diminishes the ability of p53 in inhibiting the activity of 
mTOR, suggesting that Sestrin2 is the major mediator of p53-dependent mTOR regulation. 
Moreover, p53 activates the transcription of many proapoptotic genes that also induce 
autophagy. Since Beclin 1 is a BH3-only protein that binds to Bcl-2/Bcl-xL, other BH3-only 
proteins can induce autophagy by liberating Beclin 1 from Bcl-2/Bcl-xL (Maiuri et al., 2007). 
DRAM (damage-regulated autophagy modulator) is another example of autophagy-inducing 
proapoptotic gene transcriptionally activated by p53 (Crighton et al., 2006). DRAM is a 
lysosomal protein that is required for DNA damage induced autophagy, and loss of DRAM leads 
to reduced apoptotic cell death induced by DNA damage. Therefore, consistent with its stress-
responsive roles, p53 functions as a positive regulator of autophagy regarding its transcriptional 
activity.   21 
Paradoxically, genetic deletion, siRNA-mediated knockdown, and pharmacological 
inhibition of p53 all result in induction of autophagy (Tasdemir et al., 2008). Rescuing 
experiments of the activity of p53 in different subcellular compartments have shown that 
cytoplasmic p53 inhibits autophagy, in contrast to that of the nuclear p53. p53 also negatively 
regulates autophagy by reducing the levels of mature LC3B mRNA after prolonged starvation 
(Scherz-Shouval et al., 2010). These results suggest that wild-type p53 of physiological 
expression level inhibits autophagy, and either positive or negative regulation of p53 leads to 
increased autophagy. Since p53, as a stress sensor of the cell, may be perturbed in different 
ways upon various types of stress, this provides a coordinated crosstalk between p53 and 
autophagy to relieve cellular stress or induce programmed cell death.  
 
Mutant p53 
Since p53 functions as a tumor suppressor, mutations on p53 are often implicated in 
tumorigenesis. Either as a driving mutation or by increased genomic instability, p53 is affected 
in nearly half of human cancers (Hollstein et al., 1991). However, in contrast to most of other 
tumor suppressors, the majority of the p53 mutations are missense mutations caused by single 
base substitutions (Petitjean et al., 2007). Thus, although loss of p53 tumor suppressor function 
promotes oncogenesis, the missense mutations frequently occurring in p53 may provide a gain-
of-function as a strong positive selection to further facilitate tumor development (Brosh and 
Rotter, 2009). Several lines of evidence report that there are multiple effects of p53 mutations 
(Figure 1.3A-C). In additions to the lack of wild-type p53 activity, mutant p53 contributes to 
tumor progression in various ways (Kato et al., 2003). When some mutant p53 proteins are co-   22 
 
 
 
 
Figure 1.3. The Effects of Mutations on p53  
(A) Loss of function: Mutant p53 (labeled as mu p53) does not bind to the region of DNA where 
the wild type (labeled as wt p53) normally binds, and thus has no ability to activate the target 
genes of wild-type p53 involved in tumor suppression. 
(B) Gain of function: Mutant p53 can bind to the region of DNA where the wild type does not 
bind, possibly activating or repressing the expression of a different set of genes from the wild-
type p53, which contributes to the oncogenic property of the mutant p53. 
(C) Dominant-negative effect: Mutant forms of p53 have different conformation from the wild 
type, which can explain the functions of mutant p53 discussed in (A) and (B). Moreover, some 
of the mutations on p53 can change the conformation of wild type to that of mutants, when 
expressed together. Therefore, when these mutations are generated in one copy of the 
genome leaving the other copy unaffected, the mutant p53 can repress the activity of 
functional p53. 
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Figure 1.3 (Continued). 
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expressed with the wild-type p53, the mutant interacts with the wild type to change its 
conformation in a cooperative manner into the conformation of the mutant p53 (Milner and 
Medcalf, 1991). The mutant p53 is aggregated using the nucleating sequence in the DNA-
binding domain, and it is co-aggregated with the wild-type p53 (Xu et al., 2011). This 
aggregation resembles amyloid structures that prion proteins generate (Ano Bom et al., 2012). 
Conversely, wild-type p53 can function as a chaperone for the mutant p53, maintaining a 
dynamic equilibrium between wild type and mutant p53 (Gogna et al., 2012). This suggests that 
monoallelic mutation of p53 can result in complete loss of wild-type p53 activity. Moreover, 
increased mutation rate in cancers often leads to the mutation on remaining wild-type p53 
allele, which is another mechanism of tumor progression by p53 mutation. Surprisingly, 
mutations on p53 can also render it gain novel oncogenic properties. For example, mutant p53 
can activate the transcription of genes involved in cell proliferation, such as TERT (telomerase 
reverse transcriptase) and Myc (Scian et al., 2004; Frazier et al., 1998). Furthermore, it interacts 
with other cytosolic proteins that promote tumorigenesis. Therefore, mutant p53 reorganizes 
the architecture of the cells by regulating a variety of targets in an orchestrated manner. 
  Mutant p53 is often accumulated in cancer cells due to its inability to be degraded by 
Mdm2 (Lukashchuk and Vousden, 2007). Neither does it activate the transcription of Mdm2, 
suggesting that the negative feedback loop between p53 and Mdm2 does not exist for mutant 
p53, in contrast to the wild type. In normal tissues, mutant p53 is not significantly accumulated, 
as shown in mutant p53 knock-in mice (Lang et al., 2004; Olive et al., 2004). However, loss of 
Mdm2 leads to the accumulation of mutant p53 both in normal and cancer cells, raising the 
possibility that the mutant p53 is regulated differently in cancer cells compared with normal   25 
cells. Due to its conformational properties, the stability of mutant p53 has been known to be 
regulated by chaperone proteins. Hsp90 (heat shock protein 90) contributes to the stability of 
mutant p53, and inhibition of Hsp90 results in reduced levels of mutant p53 (Lin et al., 2008). 
The mutant p53 is also known to be associated with other chaperones, such as Hsc70 and 
Hsp84 (Hinds et al., 1987; Sepehrnia et al., 1996). These results suggest that the regulation of 
the mutant p53 may be dependent on the cellular quality control. 
In Chapter 3, we utilize a small molecule inhibitor of autophagy to demonstrate the 
regulation of p53. Using the compound, we show that the class III PI3 kinase complex and p53 is 
coordinately regulated through deubiquitination. Interestingly, mutant p53 is also regulated by 
autophagy inhibitor, but the mode of regulation may be unique, involving chaperone-mediated 
autophagy.    26 
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Summary 
  Vacuolar protein sorting 34 (Vps34) complexes, the class III PtdIns3 kinase, specifically 
phosphorylate the D3 position of PtdIns to produce PtdIns3P. Vps34 is involved in the control of 
multiple key intracellular membrane trafficking pathways including endocytic sorting and 
autophagy. In mammalian cells, Vps34 interacts with Beclin 1, an ortholog of Atg6 in yeast, to 
regulate the production of PtdIns3P and autophagy. We show that Vps34 is phosphorylated on 
Thr159 by Cdk1, which negatively regulates its interaction with Beclin 1 during mitosis. 
Cdk5/p25, a neuronal Cdk shown to play a role in Alzheimer’s disease, can also phosphorylate 
Thr159 of Vps34. Phosphorylation of Vps34 on Thr159 inhibits its interaction with Beclin 1. We 
propose that phosphorylation of Thr159 in Vps34 is a key regulatory mechanism that controls 
the class III PtdIns3 kinase activity in cell-cycle progression, development, and human diseases 
including neurodegeneration and cancers.   41 
Introduction 
  Vacuolar protein sorting 34 (Vps34), a class III PtdIns3 kinase (phosphatidylinositol 3-
kinase), was first identified as a regulator of vacuolar hydrolase sorting in yeast (Herman and 
Emr, 1990). Vps34 specifically phosphorylates the D-3 position on the inositol ring of 
phosphatidylinositol (PtdIns) to produce PtdIns3P (Schu et al., 1993). In yeast, Vps34 is present 
in two complexes that are involved in the regulating autophagy (complex I) and vacuolar 
protein sorting (complex II) (Kihara et al., 2001b). In mammalian cells, Vps34 is present in 
multiple protein complexes that include regulatory proteins Beclin 1 and p150 as well as one or 
more of the following proteins: Atg14L, UVRAG, and a negative regulator Rubicon (Itakura et 
al., 2008; Matsunaga et al., 2009; Zhong et al., 2009). Dynamic regulation of Vps34 complexes 
may provide an important regulatory mechanism to control multiple vesicular trafficking 
pathways. Although the class III PI3 kinase has been recognized to play an important role in 
regulating many important intracellular and extracellular signaling events in mediating 
membrane trafficking including endocytosis and autophagy, we still know very little about the 
molecular mechanisms that regulate the interaction of Vps34 with its partners. 
  Cyclin-dependent kinases (Cdks) are critical regulators of multiple cellular processes that 
include cell-cycle progression, development, and intracellular signaling in response to external 
stimuli. Their activity is tightly regulated and restricted to specific stages of the cell cycle. Cdk5, 
which is closely related to Cdk1 but not a part of the core cell-cycle machinery, normally 
functions during the development of nervous systems by regulating neuronal migration and 
neuritic outgrowth as well as neurotransmitter signaling in the mature nervous system (Dhavan 
and Tsai, 2001). Cdk5 was found to be abnormally activated by p25, a proteolytic product of   42 
p35, the normal partner of Cdk5, to aberrantly hyperphosphorylate tau to contribute to the 
formation of neurofibrillary tangles, an important pathological event in Alzheimer’s disease 
(AD) (Patrick et al., 1999). 
  In this study, we examined the mechanism that regulates the Vps34 complexes by Cdks. 
We show that Thr159 of Vps34 can be phosphorylated by Cdk1 and Cdk5, which inhibit its 
interaction with Beclin 1. We show that phosphorylation of Thr159 in Vps34 occurs specifically 
in mitotic cells and in p25 transgenic (Tg) mice, a model of AD (Cruz et al., 2006). Our results 
demonstrate that the phosphorylation of Thr159 in Vps34 is an important regulatory event in 
the membrane trafficking in mammalian cells and may contribute to neurodegeneration in 
human diseases such as AD. 
 
Results 
Regulation of Autophagy and PtdIns3P in Mitotic Cells 
  Eskelinen et al. reported that the number of autophagosomes was reduced in 
nocodazole-arrested mitotic cells and proposed that autophagy might be inhibited during 
mitosis (Eskelinen et al., 2002). To determine if the levels of autophagy are indeed reduced 
during mitosis in an asynchronously proliferating cell population, we used human glioblastoma 
H4 cells expressing LC3-GFP, a marker of autophagosomes (Kabeya et al., 2000). We first 
observed the numbers and intensity of LC3-GFP dots in the mitotic versus interphase cells using 
fluorescent microscopy. We found that the cells in the interphase contained significantly more 
LC3-GFP-positive autophagosomes than the mitotic cells (Figure 2.1A). We quantified the 
intensity of LC3- GFP present on the autophagosomes versus the total intensity of LC3-GFP   43 
 
 
Figure 2.1. The Levels of Autophagy and PtdIns3P Are Decreased during Mitosis  
(A) Asynchronously growing H4 cells stably ex- pressing LC3-GFP were counterstained with 
Hoechst dye to visualize nuclei and fixed with 4% paraformaldehyde. The Z series were acquired 
at 603 magnification on a wide-field microscope, and deconvolved. Maximum projection 
images are shown. The levels of autophagy were assessed in interphase and mitotic cells by 
quantifying the translocation of LC3-GFP from diffuse cytosolic to punctate autophagosomal 
location from the pictures and expressed as a ratio of LC3-GFP intensity in autophagosomal 
(spot signal) versus cytosolic (diffused signal) location per cell. The data represent an analysis of 
13 mitotic and 28 interphase cells from two independent experiments. Error bars indicate 
standard deviation. *p = 0.04.  
(B) Asynchronously growing H4 cells stably expressing FYVE-dsRed were counterstained with 
DAPI to visualize nuclei and fixed with 4% paraformaldehyde. The Z series were acquired on a 
wide-field microscope at 603 magnification and deconvolved. Maximum projection images are 
shown. The levels of PtdIns3P were assessed in interphase versus mitotic cells by quantifying 
the amount of FYVE-dsRed from the pictures and expressed as number of FYVE-dsRed spots per 
cell. The data represent an analysis of 14 mitotic and 20 interphase cells from two independent 
experiments. Error bars indicate standard deviation. ***p = 0.0007. 
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Figure 2.1 (Continued).   45 
expression in the mitotic and interphase cells under normal asynchronously proliferating state 
using fluorescent microscopy with Z stack analysis. Our data indicate that the fraction of LC3-
GFP localized to autophagosomes is significantly decreased in the mitotic as compared to the 
interphase cells (p = 0.04 in two-tailed equal variance Student’s t test) (Figure 2.1A). From these 
results, we conclude that autophagy is indeed significantly reduced in mitotic cells. 
  To study the mechanism by which autophagy is inhibited in mitotic cells, we measured 
the changes in the levels of phos-phatidylinositol-3-phosphate (PtdIns3P), a key lipid messenger 
required for autophagy (Kametaka et al., 1998) during cell cycle using H4 cells expressing a 
PtdIns3P-binding reporter protein FYVE fused with a fluorescent marker protein dsRed (H4-
FYVE-dsRed) (Gaullier et al., 1998; Gillooly et al., 2000; Kutateladze et al., 1999). Analysis of 
asynchronously proliferating H4-FYVE-dsRed cells using 3D fluorescent microscopy showed a 
significant reduction in the FYVE-dsRed dots in mitotic cells as compared to the interphase cells 
(p = 0.0007), suggesting a significant reduction in the levels of PtdIns3P in mitotic cells (Figure 
2.1B). Taken together, our results indicate that a reduction in autophagic activity in mitotic cells 
is associated with a reduction in the levels of PtdIns3P and suggest that the activity of Vps34 
complex, the class III PtdIns3 kinase responsible for the production of PtdIns3P, might be 
reduced in mitotic cells. 
 
Vps34 Is a Substrate of Cdk1 
Since the levels of PtdIns3P are reduced specifically in mitotic cells, we hypothesize that 
the mitotic kinase Cdk1 might negatively regulate the activity of the class III PtdIns3 kinase 
Vps34 complex. Based on an analysis of the amino acid sequence of Vps34 using the Scansite   46 
(http://scansite.mit.edu/), Thr159 of Vps34 is a strongly predicted phosphorylation site for 
Cdk1. To examine if Cdk1 can directly phosphorylate Vps34, we incubated immunoprecipitated 
Vps34 protein with or without recombinant Cdk1/cyclin B complex in the presence of [-
32P]-
ATP. The levels of Vps34 phosphorylation were significantly increased when incubated with 
recombinant Cdk1/cyclin B complex but reduced in the presence of alsterpaullon, a specific 
inhibitor of Cdk1 (Figure 2.2A). Consistent with the phosphorylation of T159 by Cdk1, the 
phosphorylation of T159A mutant in the same reaction was significantly lower than that of WT. 
To determine if Thr159 of Vps34 is phosphorylated by Cdk1, we generated an antibody 
that specifically recognizes phosphorylated Thr159 region (anti-pT159-Vps34). As shown in 
Figure 2.2B, recognition of Vps34 by this antibody was significantly enhanced following 
incubation with Cdk1/cyclin B complex but was inhibited in the presence of roscovitine. 
Consistent with a high specificity of the anti-pThr159 Vps34 antibody used, the anti-pT159 of 
Vps34 signal was significantly reduced after phosphatase treatment. To further confirm that 
Cdk1 is the specific kinase for Vps34 phosphorylation, we immunodepleted Cdk1 from the 
mitotic cell lysate. The levels of Vps34 phosphorylation in vitro were higher after incubation 
with mitotic cell lysates than that of asynchronized lysate. Furthermore, the phosphorylation of 
T159 Vps34 in mitotic lysates was significantly reduced after immunodepletion of Cdk1 
compared to that of mock-depleted mitotic lysate (Figure 2.2C). From these results, we 
conclude that Cdk1/cyclin B can phosphorylate Thr159 of Vps34. 
 
   47 
 
 
 
Figure 2.2. Vps34 Is Phosphorylated by Cdk1 
(A) Equal amounts of purified Flag-tagged Vps34 WT or T159A protein complexes were 
incubated with active Cdk1/cyclin B1 complex in an in vitro phosphorylation assay with [-
32P]-
ATP in the absence or presence of alsterpaullon (0.1 M), and phosphorylation of Vps34 
protein was detected by autoradiography after proteins were resolved on SDS-PAGE. The ratios 
of 
32P signal versus anti-Flag signal were indicated below. 
(B) Equal amounts of purified Flag-tagged Vps34 WT complexes were incubated with active 
Cdk1/cyclin B1 complex in an in vitro phosphorylation assay with ATP in the absence or 
presence of roscovitine (1 M). The samples were either mock treated or phosphatase treated 
as indicated. Phosphorylation of Vps34 protein was detected with anti-pThr159 Vps34 antibody 
by western blotting. 
(C) Flag-Vps34 was incubated with mitotic extract after two rounds of Cdk1 depletion using 
anti-Cdk1, or mock-depleted asynchronous or mitotic 293T extracts using a control antibody. 
The amount of residual Cdk1 was measured by western blotting. Phosphorylation of Vps34 was 
measured by western blotting with anti-pThr159 Vps34 antibody.   48 
Figure 2.2 (Continued). 
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Vps34 Is Phosphorylated at T159 in Mitotic Cells 
Since Cdk1/cyclin B is specifically activated during the mitotic phase, we hypothesize 
that Thr159 of Vps34 may be phosphorylated specifically during mitosis. Exposure of 
proliferating cells to a microtubule destabilizing agent, nocodazole, induces mitotic arrest. 
293T, H4, and HeLa cells were treated with nocodazole (200 ng/ml) to synchronize these cell 
lines in the mitotic phase and the cell lysates were analyzed by western blotting using anti-
pT159-Vps34 antibody. As shown in Figure 2.3A, phosphorylation of Thr159 in Vps34 was 
increased in a time-dependent manner upon nocodazole treatment. Treatment with Cdk1 
inhibitors roscovitine (10 M) or alsterpaullon (1 M) dramatically reduced nocodazole-induced 
Thr159 phosphorylation on Vps34 (Figure 2.3B). Moreover, treatment of phosphatase after 
synchronizing H4 and HeLa cells in mitosis also resulted in decreased phosphorylation of Vps34 
as recognized by anti-pT159-Vps34 antibody (Figure 2.3C). 
  To determine whether the increase of Vps34 Thr159 phosphorylation was caused by the 
stress elicited by interference with microtubule stability or a normal cell-cycle event associated 
with mitosis, we monitored the levels of Vps34 Thr159 phosphorylation in synchronized H4 cells 
after releasing serum-starved cells from the G0/G1 block by serum addition. While the levels of 
total Vps34 protein remained relatively constant during cell cycle, the maximum level of Vps34 
Thr159 phosphorylation was detected at 36 hr post-serum addition, which coincided with the 
time when the levels of cyclin B reached its peak (Figure 2.3D). To further confirm this result, 
we analyzed the levels of Vps34 Thr159 phosphorylation in HeLa cells synchronized using 
double thymidine block procedure. As shown in Figure 2.3E, the levels of phosphorylated Vps34 
were significantly elevated at 10 hr after the release when cells were in the mitotic phase.   50 
 
Figure 2.3. Vps34 Is Phosphorylated in the Mitotic Phase  
(A) Treatment of proliferating 293T, H4, and HeLa cells with nocodazole for indicated amount of 
times led to a gradual increase of Vps34 Thr159 phosphorylation as detected by western 
blotting using anti-pT159 antibody. Anti-tubulin was used as a loading control. 
(B) HeLa cells were arrested in mitosis using 200 ng/ml nocodazole for 16 hr. Two different 
Cdk1 inhibitors, alsterpaullone (1 M) and roscovitine (10 M), reduced nocodazole-induced 
Vps34 Thr159 phosphorylation. Phosphorylation of Vps34 was detected by western blotting 
using anti-pT159 antibody. 
(C) H4 and HeLa cells were treated with nocodazole for 16 hr, and the lysates were analyzed by 
western blotting with anti-pT159 antibody with or without l phosphatase treatment as 
indicated. 
(D and E) HeLa cells were harvested after serum addition to induce synchronous cell cycle re- 
entering after 3 days of serum deprivation (D) or release from double thymidine block (E). The 
total lysates were analyzed at the indicated time points by western blotting with anti-cyclin B1 
and anti-pT159 antibody. 
(F and G) Asynchronously proliferating HeLa cells were fixed by paraformaldehyde and 
immunostained with anti-Vps34 (F) or affinity-purified anti-pThr159 Vps34 (G) antibodies and 
DAPI. Vps34, phosphorylated Vps34, DAPI, and merged images were shown in each stage of the 
cell cycle. These images were magnified from Figures S2.1A and S2.1B. Scale bar, 10 m.   51 
Figure 2.3 (Continued).   52 
Taken together, we conclude that the phosphorylation of Vps34 at Thr159 is a normal mitotic 
phase- associated event. 
  We next examined the expression and subcellular localization of Thr159-phosphorylated 
Vps34 in asynchronously proliferating HeLa cells during interphase and mitotic phase by 
immunofluorescence microscopy. In human cells, Vps34 was localized in the perinuclear area in 
the interphase (Kihara et al., 2001a). In the mitotic cells, Vps34 was evenly distributed in the 
cells after nuclear envelope breakdown (Figure 2.3F and Figure A2.1A). On the other hand, the 
signal for p-Thr159 Vps34 was largely absent in nonmitotic cells but significantly increased in 
the cells during early mitotic phase (prophase, metaphase, and anaphase) and dramatically 
reduced in the late mitotic phase (telophase/cytokinesis) (Figure 2.3G and Figure A2.1B). This 
result is consistent with the western blotting analysis as shown in Figure 2.3E: the levels of 
Thr159-phosphorylated Vps34 were significantly decreased at 14 hr after the release when 
cyclin B expression was also decreased. These data indicate that in HeLa cells, Vps34 is 
phosphorylated on Thr159 in the early mitotic phase, but dephosphorylated in the late mitotic 
phase. 
 
Cdk5 Can Also Phosphorylate Vps34 
Although Cdk5, a member of the Cdk family, does not play a role in the regulation of cell 
cycle as Cdk1, Cdk5 has also been reported to phosphorylate certain substrates of Cdk1 (Smith 
and Tsai, 2002). To test if Cdk5 can phosphorylate Vps34, we incubated immunoprecipitated 
Vps34 protein with or without recombinant Cdk5/p25 complex in the presence of [-
32P]-ATP. 
As shown in Figure 2.4A, the levels of 
32P-labeled Vps34 were increased after the incubation    53 
 
Figure 2.4. Vps34 Is Phosphorylated by Cdk5/p25  
(A) Vps34 was immunoprecipitated using anti-Flag antibody from 293T cells transfected with 
Flag-Vps34 vector and incubated in the absence or with different amounts of Cdk5/p25 
complex and [-
32P] ATP. The mixtures were resolved with 8% SDS/PAGE and subjected to 
autoradiography. Relative ratios of the 
32P signals divided by the amount of protein are 
indicated. 
(B) A schematic representation of phosphorylation sites on Vps34. The upper side shows 
phosphorylation sites detected without incubation with Cdk5/p25. The under side shows two 
additional phosphorylation sites detected only after incubation with Cdk5/p25. 
(C) Lysates from H4 cells expressing Cdk5/p25 were either untreated or treated with lPP prior to 
western blotting with anti-pThr159 Vps34 and total Vps34 antibodies. 
(D) 293T cells were transfected with indicated expression constructs of Vps34 with or without 
that of Cdk5/p25. The immunoprecipitants with anti-Flag antibody were analyzed by western 
blotting using anti-pThr159 Vps34 and anti-Flag antibodies. 
(E) H4 cells were transfected with Cdk5/p25 vectors with or without 10 M roscovitine (Ros). 
After 20 hr, the whole-cell lysates were analyzed by western blotting using anti-pThr159 Vps34 
and total Vps34 antibodies. 
(F) Western blotting analysis of CK-p25 Tg mouse forebrain lysates after induced for 2 or 5 
weeks (Tg-On) or not induced (control) (Tg-Off) using anti-pT159 Vps34, total Vps34, anti-p35, 
and anti-tubulin (as a loading control).   54 
Figure 2.4 (Continued). 
   55 
with recombinant Cdk5/p25 complex. 
  To identify the in vivo phosphorylation sites of Vps34 by Cdk5/p25, we 
immunoprecipitated Vps34 from cells cotransfected with Cdk5/p25 or vector controls and 
analyzed the sites of phosphorylation by matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) analysis. Phosphorylated Thr163, Ser164, Ser244, 
Ser282, and Ser455 of Vps34 were detected without cotransfection with Cdk5/p25. However, 
two additional amino acids in Vps34, Thr159 and Thr668, were found to be phosphorylated only 
after cotransfection with Cdk5/p25 (Figure 2.4B). 
We next tested the ability of anti-pT159-Vps34 antibody to detect Vps34 
phosphorylated by Cdk5/p25. Lysates of H4 cells transfected with Cdk5/p25 expression vector 
were prepared and either left untreated or treated with lambda protein phosphatase (lPP) prior 
to immunoblotting. Anti-pThr159-Vps34 antibody detected phosphorylated Thr159 Vps34 only 
in the lysates of cells expressing Cdk5/p25. The signal was completely removed by the 
phosphatase treatment. In contrast, the addition of phosphatase had no effect on the total 
levels of Vps34 (Figure 2.4C). 
We further confirmed the phosphorylation of Thr159 by Cdk5/p25 using Vps34 mutants. 
We analyzed the immunoprecipitates isolated with anti-Flag antibody from 293T cells 
transfected with vectors expressing Flag-tagged wild-type (WT), T159A, or T668A mutant forms 
of Vps34 in the presence or absence of Cdk5/p25 by immunoblotting using anti-pT159-Vps34 
and Flag antibodies. Although the expression levels of total Vps34 were not appreciably 
different, anti-pT159-Vps34 antibody detected a stronger signal in cells expressing Cdk5/p25 
than those without Cdk5/p25 (lanes 1 and 2, Figure 2.4D). Mutation of Thr159 to Ala (T159A)   56 
resulted in a complete loss of recognition by anti-pT159-Vps34 antibody. On the other hand, 
T688A mutation in Vps34 did not change its recognition by anti-pT159-Vps34 antibody or the 
levels of phosphorylation in the presence of cdk5/p25 (lanes 3 and 4, Figure 2.4D). These results 
demonstrate that Cdk5/p25 can phosphorylate Thr159 of Vps34. 
To further examine if Cdk5/p25 can mediate the phosphorylation of endogenous Vps34 
in cells, we analyzed the lysates of H4 cells transfected with Cdk5/p25 or vectors control with or 
without the treatment with roscovitine using anti-pT159-Vps34 antibody. As expected, Thr159-
phosphorylated Vps34 was detected in Cdk5/p25-expressing cells, and the phosphorylation was 
attenuated by roscovitine (Figure 2.4E). 
  To confirm the phosphorylation of Vps34 in vivo, we used anti-pT159-Vps34 antibody to 
examine the phosphorylation status of Thr159 site in CK-p25 Tg mouse brains after inducing 
p25 expression which activates endogenous Cdk5 (Cruz et al., 2003). As shown in Figure 2.4F, a 
significant increase in Thr159 phosphorylated Vps34 was observed after 2 and 5 weeks p25 
induction, which was when the earliest biochemical changes could be observed in this line of Tg 
mice after inducing p25 expression (Cruz et al., 2003). Taken together, we conclude that Thr159 
Vps34 can be phosphorylated by Cdk5/p25 in vitro and in vivo. 
  Since Vps34 is known to be positively regulated by p150 (Panaretou et al., 1997; Yan et 
al., 2009), we tested whether the expression of p150 had any effect on Thr159 phosphorylation 
of Vps34. We found that overexpression of p150 did not lead to T159 phosphorylation of 
Vps34, nor did it have any effect on T159 phosphorylation by Cdk5/p25 (Figure A2.2). Thus, it is 
most likely that Cdks directly target and phosphorylate Vps34. 
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Thr159 Phosphorylation Negatively Regulates the Interaction of Vps34 with Beclin 1  
  The activity of type III PI3 kinase is determined by the interaction of Vps34 with its 
regulatory subunits, including Beclin 1. Therefore, we evaluated the effect of T159 
phosphorylation on Beclin 1/Vps34 complex formation. To identify the Vps34 domain that binds 
to Beclin 1, we coexpressed individual Vps34 domains (Figure A2.3A) with domains of Beclin 1 
in 293T cells. Consistent with previous reports (Furuya et al., 2005; Liang et al., 2006), the C2 
domain of Vps34, where T159 is localized, bound to Beclin 1 (Figure A2.3B). Conversely, the 
coiled-coil domain (CCD) and the ECD of Beclin 1 were required for binding of Vps34 (Figure 
A2.3C). To determine whether Cdk5/p25 can influence the Beclin 1/Vps34 complex, we 
cotransfected 293T cells with Flag-Vps34 and GFP-Beclin 1 in the presence or absence of 
Cdk5/p25 expression. GFP-tagged Beclin 1 could be coimmunoprecipitated with Flag-tagged 
Vps34 by anti-Flag antibody in the absence of Cdk5/p25. When p25 and Cdk5 were 
coexpressed, coimmunoprecipitation of GFP-Beclin 1 with Flag-Vps34 was drastically reduced 
(Figure 2.5A). However, the interaction of Vps34 and Beclin 1 was partially rescued in the 
Cdk5/p25-expressing cells in the presence of roscovitine (Figure 2.5A), suggesting that the 
kinase activity of Cdk5/p25 was necessary for the disruption of the Beclin 1/Vps34 complex. 
Similarly, HA-tagged Vps34 could be coimmunoprecipitated with Flag-tagged Beclin 1 by anti-
Flag antibody in the absence of Cdk5/p25 expression. This interaction was significantly reduced 
in Cdk5/p25-expressing cells (Figure 2.5B). 
  To confirm that endogenous Beclin 1/Vps34 complex is regulated by Cdk5/p25, we 
transfected p25 expression vector into H4 cells and immunoprecipitated Vps34 complex using 
anti-Beclin 1 antibody. We found that the endogenous Vps34 was coimmunoprecipitated with   58 
Figure 2.5. Cdk5/p25 Disrupts Beclin 1/Vps34 Complex 
(A) 293T cells were transfected with Flag-Vps34 and GFP-Beclin 1 with or without Cdk5/p25 
expression vectors. Flag-Vps34 was immunoprecipitated with anti-Flag antibody from the 
lysates. The immunoprecipitates were blotted with anti-GFP antibody and subsequently probed 
with anti-Flag, p35, and Cdk5 antibodies.  
(B) HA-Vps34 and Flag-Beclin 1 with or without Cdk5/p25 expression vectors were transfected 
into 293T cells. The protein complexes were immunoprecipitated using anti-Flag antibody and 
analyzed by western blotting using anti-HA antibody. 
(C) H4 cells were transfected with or without p25 expression vector. Beclin 1 was 
immunoprecipitated with anti-Beclin 1 antibody from the lysates. The immunoprecipitates 
were analyzed by western blotting using anti-Vps34 antibody.  
(D) HeLa cells were synchronized in mitotic phase with nocodazole. Beclin 1 was 
immunoprecipitated with anti-Beclin 1 antibody from lysates. The immunoprecipitates were 
analyzed by western blotting using anti-Vps34 and pThr159 Vps34 antibodies. 
(E) 293T cells were transfected with Flag-tagged Vps34 WT, mutant T159A, T668A, and GFP-
Beclin 1 with or without Cdk5/p25 expression vectors. Flag-Vps34 was immunoprecipitated 
with anti-Flag antibody from the lysates. The immunocomplexes were analyzed by western 
blotting using anti-GFP and Flag antibodies.  
(F) 293T cells were transfected with Flag-tagged Beclin 1 with HA tagged Vps34 WT, mutant 
T159A, and T668A with or without Cdk5/p25 expression vectors. Flag-Beclin 1 was 
immunoprecipitated with anti-Flag antibody from the lysates. The immunocomplexes were 
analyzed using anti-HA and Flag antibodies.   59 
Figure 2.5 (Continued).   60 
endogenous Beclin 1 in the absence of p25 expression, but this interaction was disrupted by 
p25 expression (Figure 2.5C). To examine if the formation of Vps34 /Beclin 1 complex is also 
disrupted in the mitotic phase due to the Cdk1/cyclin B activity, we synchronized HeLa cells 
with 16 hr nocodazole treatment and immunoprecipitated with Beclin 1 antibody. As expected, 
this interaction was significantly reduced in mitotic as compared with asynchronous cells 
(Figure 2.5D). Taken together, we conclude that the interaction of Beclin 1/Vps34 is disrupted in 
the presence of active Cdk5/p25 or Cdk1. 
  To examine if the phosphorylation of Thr159 and/or Thr668 in Vps34 by Cdk5/p25 is 
responsible for the observed reduction of Beclin 1/Vps34 interaction, we compared the 
interaction of T159A, T668A, or WT Vps34 with Beclin 1 with or without Cdk5/p25. As shown in 
Figure 2.5E, coimmunoprecipitation of Flag-tagged WT or T688A Vps34 with GFP-tagged Beclin 
1 was inhibited by the expression of Cdk5/p25, whereas that of T159A Vps34 with Beclin 1 was 
insensitive to cdk5/p25 expression. Similarly, coimmunoprecipitation of Flag-tagged Beclin 1 
with HA-tagged WT or T688A Vps34 was reduced by Cdk5/p25 expression, while the interaction 
of flagged-Beclin 1 with T159A Vps34 was not affected by Cdk5/p25 expression (Figure 2.5F). 
Interestingly, in both experiments the phosphomutant Vps34 (T159A) showed an increased 
interaction with Beclin 1 as compared with WT Vps34 (Figures 2.5E and 2.5F). Taken together, 
these data provide strong evidence that Cdk5/p25 phosphorylation of Thr159 in the C2 domain 
responsible for interacting with Beclin 1 reduces the interaction of Vps34 with Beclin 1.   61 
Thr159 Phosphorylation Negatively Regulates the PtdIns3 Kinase Activity of Vps34 and 
Autophagy  
  Since the experiments described above demonstrated an important role of Thr159 
phosphorylation in regulating the interaction of Vps34 with Beclin 1, we wished to further 
evaluate the functional significance of this finding. We examined the levels of FYVE-dsRed dots 
in control vector or p25 expressing H4-FYVE-dsRed cells. Under nutrient-rich condition, H4-
FYVE-dsRed cells showed no significant difference in the FYVE-dsRed dots with or without p25 
expression. However, under starvation condition, known to induce autophagy, the FYVE-dsRed 
dot formation in p25-transfected H4-FYVE-dsRed cells was significantly lower than in control 
vector-transfected H4-FYVE-dsRed cells, which was recovered by roscovitine treatment (Figure 
2.6A). Thus, the expression of p25 reduces the production of PtdIns3P under starvation 
condition by phosphorylating Thr159 of Vps34. 
  To further test if Thr159 phosphorylation of Vps34 might reduce its lipid kinase activity in 
converting PtdIns to PtdIns3P, we transfected 293T cells with vectors expressing Flag-tagged 
WT Vps34 and GFP-Beclin 1 in the presence or absence of Cdk5/p25 expression. We 
immunoprecipitated Vps34 protein with anti-Flag antibody and incubated it with purified 
bovine phosphatidylinositol in the presence of [-
32P]-ATP. Extracted phospholipid products 
were separated by thin-layer chromatography. Consistent with a lower level of FYVE-dsRed dots 
in p25-expressing cells, Vps34 immunoprecipitated from cells expressing Cdk5 and p25 
demonstrated a much lower level of PtdIns3 kinase activity in converting PtdIns to PtdIns3P in 
vitro (Figure 2.6B). As a control, treatment with wortmannin, a general PtdIns3 kinase inhibitor, 
completely inhibited the PtdIns3 kinase activity (Figure 2.6B).   62 
 
Figure 2.6. Phosphorylation of Vps34 Negatively Regulates the Class III PI3 Kinase Activity 
(A) H4 cells stably expressing FYVE-dsRed were transfected with p25 expression vector. FYVE-
dsRed H4 cells were stimulated for 2 hr with HBSS as starvation condition or with roscovitine in 
HBSS to inhibit Cdk5 activity. The cells were fixed with 3.7% formaldehyde and used for 
quantifying the intensity of FYVE-dsRed dots with MetaMorph. Statistical analysis was 
performed by Student’s t test. Error bars indicate standard error. *p < 0.05.  
(B) 293T cells were transfected with vector control (lane 1), with Flag-Vps34 and GFP-Beclin 1 
(lane 2 and 4), with Flag-Vps34, GFP-Beclin 1 and Cdk5/p25 (lane 3). The whole-cell lysates were 
used for immunoprecipitation using anti-Flag antibody followed by an assay for Vps34 lipid 
kinase activity. Wortmannin (10 M) was added prior to PtdIns3P kinase assay (lane 4) as a 
positive control. 
(C) 293T cells were transfected with vector control (lane 1), with Flag-tagged WT Vps34 and 
GFP-Beclin 1 (lane 2), with Flag-tagged phosphomutant T159A Vps34 and GFP-Beclin 1 (lane 3). 
Flag-tagged Vps34 was immunoprecipitated with anti-Flag antibody and followed by an assay 
for Vps34 lipid kinase activity. Relative ratios of the 
32P signal divided by the amount of protein 
are indicated for (B) and (C).  
(D) H4 cells stably expressing FYVE-dsRed were transfected with WT or phosphomutant T159A 
Vps34, with or without Beclin 1. Cells were fixed and the number of FYVE dots was quantified. 
Error bars indicate standard error. *p < 0.01.   63 
Figure 2.6 (Continued).   64 
  As discussed above, the phosphomutant Vps34 (T159A) has shown an increased 
interaction with Beclin 1 as compared with that of WT Vps34 (Figures 2.5D and 2.5E). To 
evaluate whether this phosphomutant Vps34 T159A has increased PtdIns3 lipid kinase activity, 
we evaluated the class III PtdIns3 kinase activity in immunoprecipitated Vps34/Beclin 1 
complexes from 293T cells expressing Flag-tagged WT or phosphomutant T159A Vps34 and 
GFP-Beclin 1. Interestingly, we found that the complex with phosphomutant T159A Vps34 
exhibited dramatically higher class III PtdIns3 kinase activity than that of WT Vps34 (Figure 
2.6C). 
  To determine the effect of Vps34 T159A mutant/Beclin 1 complex in vivo, we transfected 
H4-FYVE-dsRed cells with WT or Vps34 T159A mutant, with or without Beclin 1. Consistent with 
the lipid kinase assay data, FYVE-dsRed dot formation was significantly increased only when the 
cells were cotransfected with Vps34 T159A mutant and Beclin 1 (Figure 2.6D). 
To further determine whether autophagy is regulated consistently with the lipid kinase 
activity of Vps34 by Cdk5 and the T159A mutant of Vps34, we used H4 cells expressing LC3-GFP. 
Under nutrient-rich condition in which a minimal level of autophagy occurs, transfection of p25 
did not affect the basal levels of autophagy, which was very low already. However, p25 
significantly reduced the level of starvation-induced autophagy, consistent with the decrease of 
PI3P formation by p25 (Figure 2.7A). We also tested the effect of Vps34 T159A mutant, which is 
more active than the WT Vps34. Under nutrient-rich condition, the level of autophagy was 
increased in the cells transfected with Vps34 T159A mutant. The difference of autophagy level 
between them was diminished in starved cells, suggesting that Vps34 T159A mutant partially 
mimics starvation condition (Figure 2.7B).   65 
 
Figure 2.7. Phosphorylation of Vps34 Results in the Inhibition of Autophagy 
(A) H4 cells expressing LC3-GFP were transfected with p25 expression vector. Twenty-two hours 
after the transfection, starvation was induced by culturing in HBSS only. The cells were fixed 
after 1 and 2 hr of starvation with 3.7% formaldehyde and the area of LC3-GFP dots was 
quantified using MetaMorph. Error bars indicate standard deviation. *p < 0.05.  
(B) H4 cells expressing LC3-GFP were transfected with WT or T159A Vps34 mutant. Twenty-two 
hours after the transfection, starvation was induced by culturing in HBSS only. The cells were 
fixed after 1 and 2 hr of starvation with 3.7% formaldehyde and analyzed as in (A). Error bars 
indicate standard deviation. *p < 0.05.  
(C) 293T cells were transfected with different expression vectors of WT and T668A, T668D, and 
T668E mutants in different combination and lipid kinase assays were conducted as in Figure 2.6. 
(D) 293T cells were transfected with indicated expression vectors, and lipid kinase assays were 
conducted as in Figure 2.6. Relative ratios of the 
32P signal divided by the amount of protein as 
measured by the densitometry are indicated.  
(E) H4 cells expressing LC3-GFP were transfected with WT or T159A mutant Vps34 expression 
vector with or without p25 expression vector. Twenty-two hours after the transfection, 
starvation was induced by culturing in HBSS only for 2 hr. The cells were fixed with 4% 
paraformaldehyde, and the intensity of LC3-GFP dots was quantified using MetaMorph. Error 
bars indicate standard error. ***p < 0.01.   66 
Figure 2.7 (Continued). 
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Finally, since we found that T668 can also be phosphorylated by Cdk5 (Figure 2.4B), we 
examined the requirement of T668 for the lipid kinase activity of Vps34. As shown in Figure 
2.7C, T668A, T668D, or T668E Vps34 were all inactive in the in vitro lipid kinase assay. To 
determine the relative contribution of T159 and T668 phosphorylation by Cdk5 to inhibiting the 
lipid kinase activity, we tested the activity of T159A Vps34 protein immunoprecipitated from 
Cdk5/p25-expressing cells. The lipid kinase activity of T159A Vps34 mutant was also inhibited 
by Cdk5/p25 (Figure 2.7D); furthermore, overexpression of p25 in H4 cells resulted in inhibition 
of autophagy even in the presence of T159A Vps34 overexpression (Figure 2.7E). Thus, Cdks 
may have two mechanisms to negatively regulate Vps34: phosphorylation of T159, which 
interferes with its binding to Beclin 1, and phosphorylation of T668, a residue in the catalytic 
domain that is required for the lipid kinase activity. 
 
Discussion 
Our study demonstrates a mechanism that regulates the interaction of Vps34 with its 
key partner Beclin 1 by Cdks. It provides the first example of dynamic regulation of intracellular 
PtdIns3P production in mammalian cells through phosphorylation of the class III PI3 kinase. 
Since Cdk1 is a key mitotic kinase, while Cdk5 is involved in neural development by controlling 
axonal outgrowth and neuronal migration as well as neurodegeneration (Dhavan and Tsai, 
2001) and abnormal regulation of Cdks has also been implicated in tumorigenesis (Malumbres 
and Barbacid, 2009), our study has implications for understanding of the regulation of PtdIns3P 
during cell-cycle progression, development, and in major human diseases including 
neurodegeneration and cancers.   68 
Regulation of Vps34 and Beclin 1 Interaction 
Our study provides a mechanism that regulates PtdIns3P under conditions that are not 
nutritionally limiting but when Cdks are activated. Since phosphorylation of Vps34 at Thr159 of 
the C2 domain by Cdk5 and Cdc2/Cdk1 inhibits its interaction with Beclin 1, a critical regulator 
subunit of the class III PI3 kinase complex, this mechanism may be utilized by the members of 
Cdk family to directly regulate the production and/or distribution of PtdIns3P under different 
physiological and pathological conditions. For example, phosphorylation of Vps34 in cancer cells 
by abnormally activated Cdks may provide a mechanism to lead to inhibition of class III PI3 
kinase activity and autophagy, which may in turn contribute to genomic instability (Karantza- 
Wadsworth et al., 2007). Since the stability of individual components in the Vps34 complex is 
highly dependent upon each other (Itakura et al., 2008), phosphorylation of T159 may 
accelerate the degradation of Vps34 complex. 
In the S. cerevisiae, the ATG6/VPS30 gene product is required for both autophagy and 
sorting of the vacuole resident hydrolase carboxypeptidase Y through the Vps pathway 
(Kametaka et al., 1998). In mammalian cells, in addition to regulating autophagy and endosomal 
trafficking, Beclin 1 is known as a haploinsufficient tumor suppressor (Qu et al., 2003; Yue et al., 
2003). Beclin 1 contains a BH3-only domain (Maiuri et al., 2007; Oberstein et al., 2007) and 
interacts with Bcl-2 (Pattingre et al., 2005). Since increased interaction of Beclin 1 with Bcl-2 has 
been shown to negatively regulate autophagy by competing for binding with Vps34, 
phosphorylation of Thr159 on Vps34 may release Beclin 1, which in turn may increase its 
interaction with other cellular partners and positively regulate additional Beclin 1-mediated 
cellular processes.   69 
Inhibition of Vps34 Kinase Activity by Cdk5 Mediated T668 Phosphorylation  
From a mass spectrometric analysis, we have identified T668, a residue in the catalytic 
domain of Vps34, as a Cdk5 phosphorylation site. Any mutations we introduced in this site 
totally abolished Vps34 lipid kinase activity (Figure 2.7C). Although we do not yet have an 
antibody that can monitor the phosphorylation status of T668, this result suggests that T668 is 
required for the lipid kinase activity. This result also suggests that Cdk5 may have two 
mechanisms to negatively regulate Vps34 activity: phosphorylation of T668 to inhibit its lipid 
kinase activity and phosphorylation of T159 to interfere with its binding with Beclin 1. Since 
interfering with the Vps34 and Beclin 1 interaction may disrupt the Vps34 complex and in turn 
accelerate the degradation of individual components, inhibitory effect of T159 phosphorylation 
may be long lasting. On the other hand, phosphorylation of T668 may lead to a transient 
inhibition of Vps34 lipid kinase activity, which may be rapidly reactivated with an appropriate 
phosphatase. These possibilities may be directly examined by experiments in the future. 
 
Changes in the Distributions of PtdIns3P in Mitosis 
Inhibition of Vps34 activity has been shown to lead to multiple defects in vesicular 
trafficking such as membrane receptor degradation and multivesicular body formation. 
Phosphorylation of Vps34 by Cdks, however, may lead to a redistribution of Vps34 kinase 
activity by modulating its interaction with Beclin 1 and perhaps with other partners as well, 
rather than a total inhibition of Vps34 lipid kinase activity. Since suppression of Beclin 1 
expression has been shown to lead to inhibition of autophagy (Liang et al., 1999; Zeng et al., 
2006) and PtdIns3P is known to be important for autophagy signaling, inhibition of Vps34   70 
activity may provide an important mechanism to regulate autophagy during mitosis after 
nuclear membrane breakdown. Phosphorylation of Vps34 during mitosis may function to 
selectively reduce the input to the autophagosome compartment during mitosis without 
affecting early endosomal trafficking. On the other hand, selective inhibition of membrane 
trafficking to the autophagosomes might be important to prevent the loss of the Golgi 
compartment, which undergoes a complete fragmentation during mitosis (for review, see 
Nelson, 2000). Although Beclin 1 may not be the partner for Vps34 in regulation of the vesicular 
trafficking (Zeng et al., 2006), phosphorylation of Vps34 may affect its interaction with 
additional partner(s) mediating endosome to lysosome transport, which remains to be explored 
in future studies. 
 
Cdks, Autophagy, and Neuronal Cell Death 
Our study demonstrates a mechanism by which two members of the Cdk family of 
protein kinases, Cdk1 and Cdk5, negatively regulate the production of PtdIns3P, which may in 
turn negatively regulate autophagy. In yeast, Pho85p, a member of yeast Cdk family and a 
regulator of phosphate metabolism and glycogen synthase, has been shown to be a negative 
regulator of autophagy (Wang et al., 2001). Increased autophagic activity, observed in WT cells 
entering the stationary phase where nutrient is limiting, was exaggerated in pho85 mutants. 
Thus, the Cdk family of protein kinases might have an evolutionarily conserved role in 
regulating cellular levels of autophagy. 
Induction of G1-S cyclins and Cdks as well as evidence of S phase entry and DNA 
replication have been well documented in the neurons AD (Vincent et al., 1997). Abnormal   71 
activation of Cdks, perhaps as a part of aberrant cell-cycle reactivation in postmitotic neurons, 
has been proposed to be an important underlying cause for multiple neurodegenerative 
disorders including AD (Herrup and Yang, 2007). On the other hand, activation of Cdk5 by p25 
as a result of calpain-mediated cleavage of p35 has been implicated in contributing to multiple 
pathological features of AD including tau hyperphosphorylation, formation of neurofibrillary 
tangles, and neurodegeneration (Cruz et al., 2003). Autophagy has been demonstrated to play 
an important protective role in cellular and animal models of AD and other neurodegenerative 
diseases. The ability of Cdk1 and Cdk5 to phosphorylate Vps34 described here provides a new 
mechanism by which abnormal activation of Cdks contributes to neurodegeneration by 
negatively regulating autophagy. 
 
Experimental Procedures 
Chemicals and Antibodies 
The sources of the antibodies used were as follows: monoclonal antibodies against 
tubulin and Flag (Sigma), cyclin B1 (sc-245, Santa Cruz Biotechnology), HA (HA.11) (Covance), 
GFP (Clontech), Ub (Dako), Beclin 1 (BD transduction), rabbit polyclonal antibodies against 
Beclin 1, Cdk5 (C-8), p35 (C-19) (Santa Cruz Biotechnology), and Vps34 (Zymed). Purified 
Cdk1/cyclin B and lPP were from New England Biochemical (Beverly, MA). Alsterpaullon was 
from A.G. Scientific (San Diego, CA). Chemicals were obtained from Sigma unless otherwise 
noted.   72 
Cell Synchronization 
For double thymidine block, HeLa cells were treated with 2 mM thymidine for 16–24 hr 
and released from G1/S phase in DMEM for 8 hr. HeLa cells were treated with thymidine again 
for 16–24 hr, then released from G1/S phase with DMEM for analyzing mitotic cells. 
For serum starvation synchronization, H4 cells were treated with DMEM with 0.5% 
serum for 3 days. H4 cells were released from G0 phase with DMEM with 10% serum and then 
collected in indicated time. 
 
Immunofluorescence 
For immunofluorescence analysis, H4 and HeLa cells were grown on coverslips. The cells 
were fixed with 3.7% formaldehyde, permeabilized, and blocked with 3% bovine serum albumin 
(BSA). Blocked cells were incubated with indicated primary antibody overnight at 4C. Cells 
were then incubated with Texas red-conjugated anti-rabbit IgG secondary antibody (Jackson 
ImmunoResearch) for 1 hr at room temperature. Fluorescence imaging was done on Nikon 
Eclipse 80i fluorescent microscope and quantified using MetaMorph v.7.0 software. 
 
Quantitative Fluorescent Microscopy for Mitosis 
H4-LC3-GFP or H4-FYVE-dsRed cells were grown in asynchronous cultures on glass 
coverslips, counterstained with Hoechst dye for 1 hr, and fixed for 20 min in 4% 
paraformaldehyde/PBS. Z series (0.25 m step size) were acquired on Nikon inverted TE2000E 
wide-field microscope using 603 1.4 na oil lens. The images were deconvolved using Autoquant   73 
X AutoDeblur. Quantitation was performed on maximum projection from each Z series using 
MetaMorph v7.0 software. 
 
Generation of Anti-Phosphor-Thr159-Vps34 Antibody 
In brief, phosphopeptide (DGSEPTR/K(pT)PGRTSST) was synthesized, purified, and 
conjugated to KLH by Proteintech Group (Chicago, IL) and used to immunize two rabbits. Serum 
was collected from the two rabbits after four injections. 
 
Vps34 Lipid Kinase Assay 
Flag-tagged Vps34-expressed 293T cells were immunoprecipitated with anti-Flag M2-
agarose affinity gel as immunoprecipitation assay and washed with NP-40 buffer, eluted with 
reaction buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl) and then preincubated for 10 min at 
room temperature with 10 mM MnCl2 and 2 mg sonicated phosphatidylinositol (Sigma). Finally 
we added 10 mCi [-
32P] ATP and 1 mM cold ATP for 15 min at room temperature. The kinase 
reactions were stopped by the addition of 20 ml 8M HCl and extracted with 160 ml chloroform: 
methanol (1:1). Extracted phospholipid products were separated on Silica Gel 60A (Merck). 
Plates were dried and exposed by autoradiography to visualize PtdIns3P production. 
 
Mass Spectrometry 
The Cdk5 phosphorylation sites were identified using MALDI-TOF MS in the Taplin 
Biological Mass Spectrometry Facility (http://gygi.med.harvard.edu/ facility/). 
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Supplemental Information 
Supplemental Information includes three figures and can be found at the end of the 
dissertation. 
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Abstract 
Autophagy is an evolutionarily conserved catabolic pathway important for maintaining 
cellular homeostasis. Defects in autophagy have been implicated in a wide variety of diseases 
including cancers and neurodegenerative diseases. In a small molecule screening for the 
modulators of autophagy, we identified spautin-1 as an inhibitor of autophagy. Using this 
compound, we show that the class III PI3 kinase complex and Usp10/Usp13 are under reciprocal 
regulation, and thus destabilizing one leads to the degradation of the other. By controlling the 
levels of Usp10/Usp13, the class III PI3 kinase complex also regulates the levels of p53. In this 
Chapter, we investigated the effect of inhibiting autophagy on the levels of mutant p53. We 
show that the treatment of A70, a derivative of spautin-1, leads to the degradation of mutant 
p53 and the cell death of mutant p53 expressing ES-2 ovarian cancer cells, when the cells are 
under confluent or glucose-deprived conditions. By using inhibitors and siRNAs targeting 
different protein degradation pathways, we demonstrate that the degradation of mutant p53 
induced by autophagy inhibition is primarily mediated by the chaperone-mediated autophagy, 
in contrast to that of the wild-type p53. This study describes a mechanistic distinction between 
the degradation of wild type and mutant p53.  82 
Introduction 
Class III PI3 kinase complex converts phosphatidylinositol (PI) to phosphatidylinositol-3-
phosphate (PI3P) (Schu et al., 1993). This is the only PI3 kinase complex conserved from yeast 
to human, playing a crucial role in autophagy and endosomal sorting pathway (Vanhaesebroeck 
et al., 2001). Vps34, the catalytic subunit of the kinase complex, requires other regulatory 
subunits for its enzymatic activity (Backer, 2008). In mammalian cells, Vps34 forms two 
different complexes. In addition to the core complex including Vps34, Beclin 1, and p150, the 
complex I contains Atg14L and is involved in the initiation step of autophagy, whereas the 
complex II contains UVRAG and is involved in the maturation step of autophagy and endocytic 
pathway (Matsunaga et al., 2009; Zhong et al., 2009). Despite the need of specific inhibitors for 
Vps34 for research and clinical purposes, those currently used, such as 3-MA, also target other 
classes of PI3 kinases (Seglen and Gordon, 1982; Wu et al., 2010).   
p53 is one of the best-known tumor suppressors. It primarily functions as a stress-
responsive transcription factor, regulating the expression of the wide variety of downstream 
genes (Bullock and Fersht, 2001). Those target genes work cooperatively to relieve the stress, 
for example, by repairing damaged DNA, or to induce cell cycle arrest and programmed cell 
death (Oren, 2003). Under normal condition, p53 expression remains low due to rapid 
degradation through the ubiquitin-proteasome pathway (Haupt et al., 1997). However, under 
various kinds of stress, p53 is posttranslationally modified so that its degradation is inhibited. 
Since p53 functions as a guardian against genotoxic insults, deletions or point mutations on p53 
often lead to tumorigenesis (Hollstein et al., 1991). Such mutations result in loss of 
transcriptional activation of the target genes (Kato et al., 2003). However, growing evidence   83 
supports the idea that many mutant p53 forms acquire novel oncogenic functions (Wolf et al., 
1984). Furthermore, removing mutant p53 may reduce the malignancy of tumors (Bossi et al., 
2008). 
In a high-throughput chemical screening to identify small molecules regulating 
autophagy, we identified MBCQ, a known phosphodiesterase 5 (PDE5) inhibitor, as an inhibitor 
of autophagy. By performing a diversity-oriented synthesis, we synthesized an MBCQ 
derivative, spautin-1, which potently inhibits autophagy without affecting PDE5. We report that 
spautin-1 inhibits Usp10 which deubiquitinates PI3 kinase complex, and thus also degrades p53, 
which is a substrate of Usp10 (Yuan et al., 2010). We also show that a derivative of spautin-1 
can be used to induce cell death of mutant p53 expressing cells through a caspase-independent 
mechanism. From the biochemical studies, we found that inhibition of autophagy promotes the 
degradation of the mutant p53 by chaperone-mediated autophagy. Our study demonstrates a 
novel pathway mediating the degradation of oncogenic mutant p53 proteins distinct from that 
of the wild-type p53.  
 
Results 
Identification and Characterization of Spautin-1 as an Inhibitor of Autophagy 
Spautin-1 was identified in an image-based high-throughput screen for small molecules 
regulating autophagy. Treatment of spautin-1 significantly inhibited basal level autophagy as 
shown by decreased LC3 lipidation (Figure 3.1A). To further determine the mechanism by which 
spautin-1 inhibits autophagy, we tested whether it has any effect on the class III PI3 kinase 
complex that is a key mediator of autophagy. Interestingly, all subunits tested are degraded    84 
 
 
 
 
 
Figure 3.1. Spautin-1 Inhibits Autophagy by Degrading the Class III PI3 Kinase Complex 
(A) H4-LC3-GFP cells were treated with spautin-1 (10 M) with or without E64D (5 M) for 
indicated periods of time. The cell lysates were analyzed by western blotting using anti-LC3 and 
anti--tubulin.  
(B) H4-LC3-GFP cells were incubated with MG132 (10 M) or NH4Cl (10 mM) with or without 
spautin-1 (10 M) for 6 hr. The cell lysates were analyzed by western blotting using indicated 
antibodies. -tubulin was used as a control.  
(C, D) H4-LC3-GFP cells were transfected with indicated siRNAs for 72 hr or treated with 
rapamycin (0.25 M) or spautin-1 (10 M) as indicated, the cell lysates were analyzed by 
western blotting using indicated antibodies. -tubulin was used as a control. 
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Figure 3.1 (Continued). 
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upon the treatment of spautin-1, which can be blocked by inhibition of the proteasome, but not 
the lysosome, suggesting that it is degraded by the ubiquitin-proteasome system (Figure 3.1B). 
Given that most small molecules are inhibitors instead of activators, we hypothesized that 
spautin-1 inhibits a target deubiquitinase (DUB), which leads to the increased ubiquitination 
and degradation of the class III PI3 kinase complex through the proteasome. By testing siRNAs 
targeting DUBs, we identified Usp10 and Usp13 as regulators of autophagy. Spautin-1 leads to 
the degradation of Usp10/Usp13, and knockdown of Usp10/13 reduces the expression levels of 
the class III PI3 kinase complex as spautin-1 does (Figure 3.1C). Moreover, Usp10 and Usp13 
stabilize each other. Interestingly, Usp10 and Usp13 are also degraded by knockdown of Beclin 
1, suggesting that the class III PI3 kinase complex and Usp10/Usp13 are under reciprocal 
regulation (Figure 3.1D).  
 
Regulation of p53 by the Class III PI3 Kinase Complex and Spautin-1 
The interdependence of the class III PI3 kinase complex and Usp10/Usp13 raised a 
question if the levels of PI3 kinase complex affect the expression levels of p53, which is 
regulated by Usp10/Usp13. In the cell line tested, knockdown of Beclin 1 leads to the 
degradation of p53 (Figure 3.1D). This is also consistent with the finding that Beclin 1 is a 
haploinsufficient tumor suppressor, and the patterns of tumors in BECN1
+/- mice are similar to 
those in p53
+/- mice (Qu et al., 2003; Jacks et al., 1994). To test this hypothesis, an eight-week 
old BECN1
+/- mouse and its wild-type littermate were sacrificed, and the heart, lung, and liver 
tissues were harvested from them. Consistent with the previous report that the levels of the 
class III PI3 kinase complex are interdependent, all subunits of PI3 kinase complex tested are   87 
reduced in BECN1
+/- mouse compared with BECN1
+/+ mouse (Itakura et al., 2008; Figure 3.2A). 
The expression levels of Usp10 and p53 are also decreased in BECN1
+/- mouse. However, 
autophagy is not significantly defective. Since the basal levels of autophagy as well as the 
expression levels of p53 are low in normal condition, lung fibroblasts were treated with 
rapamycin and MG132 to better visualize the difference of autophagy and p53, respectively. 
The accumulation of p53 by MG132 is significantly lower in BECN1
+/- fibroblasts, whereas 
rapamycin strongly induces autophagy in both cell lines, suggesting that the effect of Beclin 1 
heterozygosity might be stronger on p53 levels than on autophagy (Figure 3.2B). To further 
analyze the effect of spautin-1 on DNA damage induced p53 activation, HT-1080 cells with wild-
type p53 were treated with doxorubicin to induce DNA damage. Consistent with the previous 
observations, spautin-1 reduces p53 accumulation by doxorubicin treatment (Figure 3.2C).  
 
A70, a Derivative of Spautin-1 Shows Specific Cytotoxicity on Confluent Cells with Mutant p53  
Although spautin-1 has been shown to degrade wild-type p53, its expression level is 
very low in normal conditions, and thus it is difficult to see any p53 related physiological effect 
of spautin-1. In contrast, mutant p53 is more strongly expressed because it is frequently 
accumulated in cancer cells. Moreover, the expression levels of mutant p53 have an effect on 
various aspects of the cellular physiology to promote oncogenesis. From the structure-activity 
relationship, we identified a derivative of spautin-1, A70. It is about 100-fold more potent than 
spautin-1, with the working concentration of 100nM. Since it has been known that p53 
mutation rate is high in breast and ovarian cancers, we tested the effect of A70 in some ovarian 
cancer cell lines with different p53 background (Schuijer and Berns, 2003). Interestingly, A70    88 
 
 
 
 
 
Figure 3.2. p53 is Reduced by Beclin 1 Heterozygosity or Spautin-1 Treatment 
(A) Heart, lung and liver tissues of newborn BECN1
+/+ and BECN1
+/- mice were isolated and 
analyzed by western blotting using indicated antibodies. Anti-actin was used as a loading 
control. 
(B) Lung fibroblasts from BECN1
+/+ and BECN1
+/- mice were treated with 100nM rapamycin 
(Rap) for 0.5 hrs or 10M MG132 for 5 hrs, and cell lysates were analyzed by western blotting. 
Anti-actin was used as a loading control. 
(C) HT-1080 fibrosarcoma cells with wild-type p53 background were treated with 1M 
doxorubicin (Dox) to induce DNA damage and/or 10M spautin-1 for 5 hrs, and cell lysates 
were analyzed by western blotting. 
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Figure 3.2 (Continued). 
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only induces cell death of confluent cells with mutant p53 background (Figure 3.3A, B). 
Dispersed cells or p53-null cells do not undergo cell death upon A70 treatment. Moreover, 
knockdown of the mutant p53 in ES-2 cells results in the resistance to A70 (Figure 3.3C). 
Consistently, overexpressing mutant p53 in SKOV-3 cells that do not express p53 renders the 
cells sensitive to A70, suggesting that expression of mutant p53 is necessary for the sensitivity 
to A70 (Figure 3.3D).   
To explain the effect of A70 on mutant p53 expressing confluent cells, we chose ES-2 
cells with a missense mutation on p53 (S241F) for molecular studies, based on the expression 
levels of p53, and the sensitivity to A70 (Figure 3.4A). In ES-2 cells, the degradation of mutant 
p53 and cell death are only induced under confluent condition after A70 treatment (Figure 
3.4B). Interestingly, mutant p53 is degraded earlier than Usp13, suggesting that mutant p53 
may not be direct substrate of Usp13 (Figure 3.4C). Deubiquitinating enzymes plays an 
important role in recycling free ubiquitins to maintain ubiquitin homeostasis in the cell, and 
thus A70-mediated degradation of multiple DUBs may render the cells suffer from the lack of 
available ubiquitins because the levels of free ubiquitin depend more on the recycling than 
synthesis or degradation. Consistent with this idea, the levels of free ubiquitin is lower in 
confluent cells, and even further depleted by A70 treatment (Figure 3.4D). 
To determine how mutant p53 is degraded upon A70 treatment, we first checked the 
ubiquitination status of the mutant p53 because wild-type p53 is known to be constitutively 
ubiquitinated in normal conditions. However, there has not been much known about the 
ubiquitination of mutant p53 so far except for some selected mutations (Lukashchuk and 
Vousden, 2007). The mutant p53 in ES-2 cells is not as highly ubiquitinated as that of the wild-     91 
 
 
 
 
Figure 3.3. A70 Specifically Induces Cell Death in Mutant p53 Expressing Cells 
(A) Ovarian cancer cell lines with different genetic background of p53 were treated with A70, 
and then observed under phase contrast microscope. The magnification of the objective lens is 
40X. 
(B) Cell viability in (A) was analyzed by measuring cellular ATP levels. Error bars indicate 
standard deviation. 
(C) ES-2 cells were infected with retroviruses expressing indicated shRNAs and treated with 
A70. Cell viability was analyzed by measuring cellular ATP levels. Error bars indicate standard 
deviation. p53 expression was confirmed by western blotting. 
(D) SKOV-3 were infected with retroviruses expressing indicated constructs and treated with 
A70. Cell viability was analyzed by measuring cellular ATP levels. Error bars indicate standard 
deviation. p53 expression was confirmed by western blotting. 
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Figure 3.3 (Continued). 
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Figure 3.4. Mutant p53 Is Degraded by A70 in Confluent Cells 
(A) Different cell lines were grown until confluence and harvested. Protein levels were analyzed 
by western blotting.  
(B) ES-2 cells were treated with 100nM A70 and harvested at different time points as indicated. 
Protein levels were analyzed by western blotting. 
(C) ES-2 cells were treated with different concentration of A70 and harvested at different time 
points. Protein levels were analyzed by western blotting. 
(D) ES-2 cells were treated with 100nM A70 as indicated and harvested. Protein levels were 
analyzed by western blotting. The same anti-Ub antibody was used to detect both poly-
ubiquitinated proteins and free monoubiquitins. 
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Figure 3.4 (Continued). 
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type p53 in HCT116 cells in the absence or in the presence of A70 (Figure 3.5A, B). Moreover, 
neither cell death nor the degradation of p53 by A70 is rescued by the inhibition of the 
proteasome (Figure 3.5C). In the cells with wild-type p53, the treatment of A70 leads to the 
degradation of p53 by inhibiting Usp10/Usp13, and thus either A70 or knockdown of 
Usp10/Usp13 is sufficient to remove p53. However, knockdown of Usp10 or Usp13 does not 
have any effect on the levels of the mutant p53 (Figure 3.5D). Interestingly, reduced levels of 
Usp10 or Usp13 delay A70 mediated degradation of mutant p53, suggesting that Usp10/Usp13 
may have some indirect effect on A70 sensitivity. 
Since A70 leads to the degradation of mutant p53 only in confluent cells, we asked what 
aspect of confluence sensitizes the cells to A70. We found that glucose in the media is almost 
used up in 24 hours when the cells are confluent and tested whether glucose deprivation has 
any effect on A70 sensitivity. Interestingly, p53 is degraded even in dispersed cells when the 
media is glucose-free (Figure 3.6A). In glucose-free media, p53 starts to be degraded in two 
hours after A70 treatment, as opposed to normal media in which p53 in confluent cells is 
degraded in 24 hours (Figure 3.6B). From these results, we suppose that when A70 is added in 
fresh media with glucose, A70 does not have any effect on p53 until glucose in the media is 
used up, which takes about 24 hours. To determine how mutant p53 is degraded in glucose-
free media, we tested different inhibitors that block several known protein degradation 
pathways. E64d turned out to inhibit mutant p53 degradation suggesting that p53 is degraded 
through the lysosomal pathway (Figure 3.6C). Consistently, we observe mutant p53 is more 
rapidly degraded upon the treatment of proteasome inhibitors because inhibition of the 
proteasome leads to the activation of lysosomal pathway to compensate. However, none of the    96 
 
 
 
 
Figure 3.5. Mutant p53 in ES-2 Cells Is Degraded by Proteasome-independent Pathway  
(A) HCT116 and ES-2 cells were transfected with HA-Ub and harvested either when they were 
confluent, or still proliferating. MG132 was added 6 hours before harvesting, and p53 was 
immunoprecipitated. Ubiquitination of p53 was analyzed by western blotting.  
(B) ES-2 cells were transfected with HA-Ub and treated with A70 for 24 hours followed by 6 
hour MG132 treatment. Ubiquitination of p53 was analyzed as in (A).  
(C) Increasing concentration of Velcade was treated with or without 100nM A70 on ES-2 cells. 
The cells were either harvested for western blotting or analyzed by ATP assay to measure cell 
viability. Error bars indicate standard deviation. Western blotting analysis was done only for the 
confluent cells.  
(D) ES-2 cells were transfected with indicated siRNAs. After 48 hrs of transfection, cells were 
treated with 100nM A70 and harvested. Cell lysates were analyzed by western blotting. 
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Figure 3.5 (Continued). 
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Figure 3.6. Mutant p53 Is Degraded by A70 in Glucose-deprived Condition  
(A) ES-2 cells were treated with 100nM A70 for 24 hours in normal glucose or glucose-free 
media. Cell lysates were harvested and analyzed by western blotting. * non-specific band.  
(B) ES-2 cells were treated with different concentration of A70 in glucose-free media and 
harvested at different time points. Protein levels were analyzed by western blotting.  
(C) ES-2 cells were treated with different inhibitors with or without A70 for 2 hours in glucose-
free media. Cell lysates were harvested and analyzed by western blotting. The bands were 
quantified by densitometry. The relative ratios of p53 are indicated. 
(D) ES-2 cells were treated with different inhibitors with or without the treatment of A70 as 
indicated and the cellular ATP levels were measured. Error bars indicate standard deviation. 
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Figure 3.6 (Continued). 
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inhibitors blocks cell death induced by A70, possibly due to the toxicity of the inhibitors 
because in glucose-free conditions the cells heavily depend on recycling (Figure 3.6D). 
Therefore, A70 as a potent inhibitor of autophagy will be toxic to the cells under nutritional 
deprivation condition. This cell death is not caspase-dependent apoptotic cell death or RIPK1 
kinase-dependent necrotic cell death because neither zVAD nor Nec-1 has any protective effect. 
Interestingly, degradation of p53 is not as much inhibited by another lysosomal inhibitor, 
Bafilomycin A1 (data not shown). Since Bafilomycin A1 inhibits lysosomal degradation of 
autophagic cargoes by blocking the fusion between autophagosome and lysosome, this 
suggests that mutant p53 is degraded by other lysosomal pathway than autophagy. This is not 
surprising because the degradation of mutant p53 is triggered by A70, which is an inhibitor of 
autophagy.   
To further study the mechanism of mutant p53 degradation, we hypothesize that p53 is 
degraded by chaperone-mediated autophagy (CMA) because it is the known to be activated 
when macroautophagy is inhibited. Moreover, p53 contains two consensus pentapeptide 
sequences, (200NLRVE204) and (340FRELN344), to be substrates for CMA (Orenstein and Cuervo, 
2010). We show that p53 degradation is inhibited by knockdown of Hsc70 or Lamp-2A in the 
CMA pathway (Figure 3.7A, B). Interestingly, the inhibition has a strong correlation with the 
knockdown efficiency. We also show that mutant p53 binds to Hsc70 and Lamp-2A, further 
confirming that p53 is degraded by CMA pathway upon A70 treatment (Figure 3.7C). It is also 
possible that mutant p53 is one of many substrates that are degraded by CMA upon A70 
treatment. However, the possibility of massive non-specific degradation was excluded by 
comparing the total protein expression patterns by Ponceau S staining.  101 
 
 
 
 
 
 
Figure 3.7. Mutant p53 Is Degraded by CMA upon A70 Treatment  
(A, B) ES-2 cells were transfected with indicated siRNAs. After 48 hours, they were treated with 
100nM A70 for 24 hours in confluent condition. Cell lysates were harvested and analyzed by 
western blotting. The bands were quantified by densitometry. The relative ratios of p53 are 
indicated.  
(C) ES-2 cells were treated as indicated with 100nM A70 for 2 hours, and p53 was 
immunoprecipitated. Coimmunoprecipitated proteins were analyzed by western blotting. Input 
samples are 5% of the lysates used for immunoprecipitation. 
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Figure 3.7 (Continued). 
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Discussion 
Autophagy has been proposed to be involved in tumor suppression. However, most of 
the known tumor suppressors in the autophagy pathway are the subunits of the class III PI3 
kinase complex, rather than downstream effectors, suggesting that the kinase complex has 
autophagy-independent anti-tumor function. Here, we propose a model in which loss of the 
subunits of the class III PI3 kinase complex can lead to reduced levels of p53. This adds another 
layer of explanation as to how the class III PI3 kinase complex suppresses tumor formation. A 
deficiency in any subunit of the class III PI3 kinase complex may reduce the effectiveness in 
cellular quality control, and thus subject to higher level of stress. Moreover, inability to mitigate 
cellular stress when cells have reduced levels of p53 may further promote tumorigenesis. 
As opposed to the earlier stage of tumorigenesis, autophagy functions to promote the 
tumor survival at the later stage (White and DePaola, 2009). For this reason, autophagy 
inhibitors could be useful in cancer treatment when used together with the chemotherapy. 
Although this combination therapy can lead to increased cytotoxicity against the tumors, other 
proliferating cells in the body such as hematopoietic stem cells will be seriously affected. A70, 
however, specifically targets mutant p53 in confluent cells. Given that most cells in solid tumor 
are surrounded by neighboring cells and have difficulty in the access of nutrients, tumors 
harboring mutant p53 may be susceptible to A70. Furthermore, mutant p53 tend to be more 
accumulated in tumor cells compared with the normal cells, which may render the tumor cells 
more sensitive to the loss of mutant p53. All together, further studies with A70 on various in 
vivo cancer models with different p53 background will help to develop a mechanism-based 
therapeutic method for cancers.   104 
Experimental Procedures 
Chemicals and Antibodies 
The sources of the antibodies used were as follows: mouse monoclonal antibodies 
against tubulin (Sigma), p53 (Cell Signaling Technology), and Lamp-2A (Santa Cruz 
Biotechnology), rabbit polyclonal antibodies against LC3 (Novus Biologicals), Hsc70, Vps34, 
Usp13 (Proteintech Group), Usp10, p150 (Abcam), Beclin 1 (Santa Cruz Biotechnology), UVRAG 
(Sigma), p53, Atg14L (Cell Signaling Technology), and ubiquitin (Dako). 
 
Immunoprecipitation 
For interaction studies, cells were harvested with lysis buffer (50mM Tris-HCl pH7.5, 150mM 
NaCl, 1mM EDTA, 1% NP-40 and protease inhibitor cocktail), and incubated overnight with p53 
antibody (Cell Signaling Technology). After incubating with protein A/G beads (Thermo 
Scientific) for two hours, the beads were washed four times with the lysis buffer. Protein 
sample buffer was added to the beads to denature the immunoprecipitated proteins. After 
harvesting the cells, all experiments were performed at 4C or on ice. For ubiquitination 
studies, RIPA buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 1mM EDTA, 1% Triton-X, 0.1% SDS, 
0.5% sodium deoxycholate, and protease inhibitor cocktail) was used. The rest of the procedure 
is the same as described above.   105 
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Chapter 4 
 
Conclusions   108 
  Autophagy is a stress-responsive mechanism of the cells, and thus is tightly regulated by 
environmental cues. The class III PI3 kinase complex is in the center of the regulation because 
most of the signals regulating autophagy in nutrient-rich conditions also regulate the class III 
PI3 kinase complex (Lipinski et al., 2010). Nevertheless, the mechanisms by which the class III 
PI3 kinase complex is regulated are not well understood. 
In Chapter 2, we demonstrate that Vps34, the catalytic subunit of the class III PI3 kinase 
complex is negatively regulated by Cdk1 and Cdk5. Phosphorylation of Vps34 by those Cdks 
results in the dissociation of Vps34 from its regulatory subunit Beclin 1, leading to decreased 
lipid kinase activity of Vps34 and inhibition of autophagy. Therefore, autophagy is inhibited in 
mitotic cells, and post-mitotic cells with elevated Cdk5 activity.  
Since cell division only occurs when the cells are surrounded with ample nutrients and 
growth factors, there is less need for the cells to activate autophagy. Moreover, in dividing cells, 
inhibition of autophagy may contribute to the preservation of important cellular components. 
Although growing evidence supports the selective autophagic degradation of cellular cargoes, 
cells will not be able to block non-selective degradation of unintended cellular components 
unless cells also counter-select autophagic cargoes. Especially during mitosis, when the nuclear 
membrane is fragmented and the genetic material is exposed to cytoplasm, the possibility of 
chromosome loss by autophagy must be avoided. This hypothesis may be tested by over-
activating autophagy in dividing cells with the induction of DNA double strand break.  
Another plausible explanation is that inhibition of autophagy in mitosis prevents the 
premature degradation of midbody ring. Midbody ring is a physical barrier between two 
daughter cells after cell division, and it has been shown to be degraded by autophagy (Pohl and   109 
Jentsch, 2009). Midbody ring formation is important to guarantee the completion of cytokinesis 
and the separation of two daughter cells. Thus, autophagy may be reactivated after the cell 
division is completed to degrade the midbody ring. In this case, forced activation of autophagy 
in mitosis may result in the polynucleated cells due to abnormal cytokinesis. 
In post-mitotic neurons, elevated Cdk5 activity has been known to be associated with 
neurodegeneration (Cruz et al., 2003). Since neurons are not able to dilute intracellular toxic 
materials by cell division, cellular quality control by autophagy is extremely important. This is 
supported by the observations that brain-specific inhibition of basal autophagy in mice leads to 
the neurodegenerative features (Komatsu et al., 2006; Hara et al., 2006). Therefore, inhibition 
of autophagy by Cdk5 is thought to contribute, at least in part, to the Cdk5-mediated 
neurodegeneration.  
Activated Cdk1 and Cdk5 phosphorylate T159 site on Vps34. T159A mutant of Vps34 
interacts with Beclin 1 more strongly than the wild-type Vps34, and the interaction between 
mutant Vps34 and Beclin 1 is not disrupted by the expression of Cdk5, suggesting that this 
phosphorylation site is critical for the interaction. Interestingly, we found that the T159D and 
T159E mutants give the same results as the T159A mutant. This raises a possibility of a putative 
mediator that only binds to pT159, but not to the mutants. Cdk1 and Cdk5 are proline-directed 
serine/threonine protein kinases that phosphorylate SP/TP sites to generate pSP/pTP, which 
are recognized by a peptidyl-prolyl isomerase Pin1 (Ranganathan et al., 1997). This implies that 
any substrate of Cdk1 and Cdk5 can be a putative substrate of Pin1 when phosphorylated. 
However, whether Pin1 is involved in the regulation of Vps34 remains to be investigated.    110 
In Chapter 3, we report another mechanism by which the class III PI3 kinase complex is 
regulated. Upon starvation, the activity of the class III PI3 kinase complex is increased in a 
couple of hours, suggesting that it is regulated by post-translational modifications. Using a small 
molecule inhibitor of autophagy, we report ubiquitination and deubiquitination as important 
regulatory mechanisms in the pathway. Interestingly, the class III PI3 kinase complex and p53 
share the deubiquitinases. This provides a regulatory interaction between the class III PI3 kinase 
complex and p53, supporting the tumor-suppressive role of the kinase complex. 
Beclin 1 heterozygous mice spontaneously develop tumors in different tissues (Qu et al., 
2003; Yue et al., 2003). It has been thought for a long time that this tumorigenesis is attributed 
to reduced autophagy. However, knockout of essential autophagy gene Atg7 only results in 
benign tumors, which is different from the aggressive tumor phenotype of Beclin 1
+/- mice 
(Takamura et al., 2011; Qu et al., 2003). Instead, the tumor patterns of Beclin 1
+/- mice is similar 
to that of p53
+/- mice, further supporting the idea that the tumorigenicity of monoallelic loss of 
Beclin 1 is due to compromised p53 (Jacks et al., 1994). 
A plausible explanation for concerted regulation of the class III PI3 kinase complex and 
p53 may be related to p53 induced cell death triggered by cellular stress. Although prolonged 
inhibition of autophagy is detrimental to the cells, temporary inhibition of autophagy may only 
cause some damage in the cells that can be overcome and repaired later by induction of 
autophagy and other stress-responsive pathways. Therefore, cells need to down-regulate the 
stress threshold for cell death when autophagy is compromised, which is achieved by transient 
decrease of p53. Alternatively, decreased activity of p53 may be a negative feedback 
mechanism of the cells to recover the levels of autophagy. Since p53 of physiological expression   111 
level is shown to inhibit autophagy, degradation of p53 induces autophagy (Tasdemir et al., 
2008). Although the activation of p53 also leads to increased autophagy, this is a long term and 
sustained effect because it involves gene transcription. Thus, any perturbation of the class III 
PI3 kinase complex may down-regulate p53 to rescue the levels of autophagy to maintain 
homeostasis. 
In contrast to that of the wild-type p53, mutant p53 is regulated in a distinctive 
mechanism by the autophagy inhibitor. Misfolded mutant p53 can interact with various 
chaperones including some of which are involved in chaperone-mediated autophagy (CMA). 
Therefore, mutant p53 is likely to be degraded by CMA that is up-regulated by inhibition of 
autophagy. Since mutant p53 is implicated in a wide range of cancers, selective degradation of 
mutant p53 can be used for therapeutic purposes, for the following reasons. First, removal of 
mutant p53 has been reported to ameliorate the tumor phenotype in mice, suggesting that the 
expression level of mutant p53 correlates with the aggressiveness of the tumor (Bossi et al., 
2008). Moreover, mutant p53 tends to be accumulated only in the cancer cells, instead of 
normal cells. Thus, cancer cells can be selectively targeted over normal cells by degrading 
mutant p53. From the experiments, we also claim that mutant p53 is degraded by A70 only in 
confluent or glucose-deprived cells, which is a hallmark of cancer cells. This may allow us to 
develop a therapeutic method to specifically induce cell death in cancer cells, which has been 
an issue for a long time, due to the cytotoxicity of many chemotherapeutic agents towards 
normal cells. However, in vivo studies using mutant p53 mouse models have yet to be 
performed to further demonstrate the effect of A70 on cancers.   112 
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Abstract 
Necroptosis, also known as programmed necrotic cell death, is a cell death pathway 
dependent of RIPK1 and its interacting partners. In L929 cells, inhibition of caspase-8 by zVAD 
induces RIPK1-dependent necrotic cell death. In this model, autophagy has been shown to play 
a crucial role, and thus inhibition of autophagy protects the cells from cell death, hence 
referred to as autophagic cell death. We report that spautin-1, a novel autophagy inhibitor we 
identified in a screen, protects zVAD induced cell death in L929. Spautin-1 also inhibits 
necroptosis induced by TNF, suggesting that it is involved in the pathway downstream of 
TNF. We also show that the class III PI3 kinase complex interacts with RIPK1/EDD complex, 
and UVRAG is ubiquitinated by EDD. From the observation, we suppose that autophagy is 
directly regulated at earlier time point by RIPK1/EDD complex rather than induced by cell 
damage in the course of cell death.  116 
Introduction 
Cells undergo programmed cell death, when triggered by death signals. Depending on 
the morphology and key players of cell death, it can be divided into subcategories. Necroptosis 
is a subset of necrotic cell death that is tightly regulated by signaling pathways (Christofferson 
and Yuan, 2010). It was defined by the identification of a small molecule Nec-1, which 
specifically inhibits necrotic cell death triggered by death signals (Degterev et al., 2005). 
Necroptosis is characterized by necrotic cell morphology including substantial increase of 
autophagy. In this pathway, receptor interacting protein kinase 1 (RIPK1) plays a crucial role, 
and its kinase activity is indispensible (Holler et al., 2000; Degterev et al., 2008). RIPK1 forms a 
complex to mediate down-stream signaling including NF-kB activation, apoptosis, and 
necroptosis. Depending on the environment of the cell, RIPK1 binds to different proteins to 
determine which pathway to turn on.  
In mouse fibroblast L929 cells, pan-caspase inhibitor zVAD or knockdown of caspase-8 
induces necroptosis. Interestingly, inhibition of autophagy by using chemical inhibitors 
targeting Vps34, or by knockdown of autophagy genes increases the cell survival upon zVAD 
treatment (Yu et al., 2004). In a genome-wide siRNA screen to identify a regulator of 
necroptosis, knockdown of EDD has been shown to inhibit zVAD induced cell death in L929 cells 
(Hitomi et al., 2008). EDD is an E3 ligase involved in DNA damage checkpoint, and often 
affected in cancer cells (Henderson et al., 2006; Clancy et al., 2003). In the necroptosis pathway, 
EDD has been shown to interact with RIPK1 and mediate TNF secretion upon zVAD treatment 
(Christofferson et al., 2012). The TNF signaling cascade is crucial in zVAD induced necroptosis   117 
pathway because knockdown of TNF receptor or neutralizing TNF with antibodies protects 
L929 cells from zVAD induced cell death. 
Here, we show that a small molecule inhibitor of autophagy, spautin-1, that we 
identified in a screen also protects L929 cells from necroptosis. We also demonstrate the 
interaction between RIPK1/EDD complex and the class III PI3 kinase complex, suggesting the 
regulation of autophagy by RIPK1/EDD complex. 
 
Results 
Spautin-1 Protects L929 Cells from Autophagic Cell Death  
Since spautin-1 specifically inhibits autophagy, we tested whether spautin-1 protects the 
cells from necrotic cell death in L929 cells. Similar to what has been shown with catalytic 
inhibitors of Vps34, spautin-1 inhibits cell death triggered by zVAD (Figure A.1A, B). 
Interestingly, it also protects L929 cells from TNF induced cell death, whereas knockdown of 
autophagy genes only rescues zVAD-induced necroptosis. Those two different signals require 
TNF receptor in common, and spautin-1 reduces the expression levels of TNF receptor, which 
explains why spautin-1 blocks both pathways (Figure A.1C). However, spautin-1 does not block 
the necrotic pathway in FADD-/- Jurkat cells which does not require autophagy (Figure A.1D). 
 
The Class III PI3 Kinase Complex Interacts with RIPK1/EDD Complex  
To further study the relationship between autophagy and necrotic cell death, we 
identified interaction partners of PI3 kinase complex in the Drosophila system. Among these, 
we identified Hyd, a fly homologue of EDD, as an interaction partner of UVRAG. In 293T cells,    118 
 
 
 
 
Figure A.1. Inhibition of zVAD and TNF Induced Cell Death in L929 Cells by Spautin-1 
(A) L929 cells were treated with 20uM zVAD or 20ng/ml TNF with or without 20uM spautin-1. 
24 hours after treatment, cellular ATP levels were measured.  
(B) L929 cells were treated as in (A) and the cells were stained with Sytox Green labeling 
membrane permeabilized cells and Hoechst labeling all cells. The ratio of Sytox Green positive 
cells to Hoechst positive cells was measured using high-throughput microscope. Error bars 
indicate standard deviation. * p<0.05, *** p<0.01.  
(C) L929 cells were treated with spautin-1 and/or zVAD as indicated for 8 hours and harvested. 
Cell lysates were analyzed by western blotting. 
(D) FADD-/- Jurkat cells were treated with different concentrations of TNF with or without 
spautin-1 for 16 hours and the cells were stained with Sytox Green labeling membrane 
permeabilized cells and Hoechst labeling all cells. The ratio of Sytox Green positive cells to 
Hoechst positive cells was measured using high-throughput microscope. Error bars indicate 
standard deviation.   
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EDD coimmunoprecipitates with UVRAG and the interaction is reduced under various insults 
(Figure A.2A). EDD also interacts with Vps34 and Beclin 1, which are the core subunits in the PI3 
kinase complex (Figure A.2B). However, EDD does not coimmunoprecipitate with Atg14L, 
suggesting that EDD specifically interacts with UVRAG containing complex instead of Atg14L 
containing complex. Since EDD has been shown to interact with RIPK1, the interaction between 
RIPK1 and the class III PI3 kinase complex was also tested. As opposed to EDD, RIPK1 interacts 
both with Atg14L and UVRAG as well as Vps34 and Beclin 1, suggesting that RIPK1 and EDD 
might regulate the class III PI3 kinase complex by more than one mechanism (Figure A.2C). To 
determine the mechanism by which RIPK1/EDD complex regulates the class III PI3 kinase 
complex, we tested if EDD has an E3 ligase activity on UVRAG. Overexpression of EDD leads to 
UVRAG ubiquitination, which is increased with the treatment of MG132 suggesting that 
ubiquitinated UVRAG is subject to the proteasomal degradation (Figure A.2D). Since both EDD 
and the class III PI3 kinase complex play important roles in zVAD induced cell death, we suppose 
that EDD mediates L929 cell death, at least in part by degrading UVRAG. Consistent with this 
hypothesis, UVRAG is degraded after zVAD treatment (Figure A.2E). Moreover, knockdown of 
UVRAG sensitizes L929 cells to zVAD (Figure A.2F). However, further studies will be necessary to 
delineate the mechanism by which RIP1 and EDD coordinately regulate the class III PI3 kinase 
complex to induce autophagic cell death in L929 cells. 
 
Discussion  
Autophagy has been reported to be significantly increased in necroptosis (Degterev et 
al., 2005). However, whether autophagy contributes to necroptosis depends on the cell types    121 
 
 
 
 
Figure A.2. Interaction of the Class III PI3 Kinase Complex with RIP1/EDD  
(A - C) 293T cells were transfected with indicated expression vectors. After 24 hrs of 
transfection, cell lysates were harvested and immunoprecipitated using agarose beads coated 
with Flag antibody, and coprecipitated proteins were analyzed by western blotting.  
(D) 293T cells were transfected with indicated expression vectors. After 24 hrs of transfection, 
cells were harvested using denaturing lysis buffer containing 8M urea. 6x His-tagged ubiquitin 
was pulled down by Ni
2+ beads, and the ubiquitinated proteins were analyzed by western 
blotting.  
(E) L929 cells were treated with zVAD for indicated time. Cell lysates were harvested and 
analyzed by western blotting. 
(F) L929 cells were treated with four different UVRAG siRNAs. After 48 hours, they were treated 
with zVAD for 24 hours. Cell lysates were harvested and analyzed by western blotting. For the 
viability assay, cellular ATP levels were measured.  
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and death signals. Although the production of ROS and mitochondrial damage occurring during 
necroptosis may lead to the activation of autophagy, the detailed mechanism of autophagy 
induction in necroptosis is still elusive (Nakagawa et al., 2005). Moreover, in autophagic cell 
death, autophagy must be activated before the cell is severely damaged because autophagy is a 
driving force for cell death. In zVAD induced autophagic cell death model, catalase is degraded 
by autophagy, resulting in increased ROS (Yu et al., 2006). Therefore, in this case, autophagy is 
activated before ROS production. In our studies, we show that RIPK1 and EDD that play 
important roles in the early step of necroptosis interact with the class III PI3 kinase complex. 
This suggests the possibility that autophagy may be regulated by RIPK1 directly in the early step 
of necroptosis in general, considering that the activity of RIPK1 is indispensible for most of the 
necroptotic models. 
 
Experimental Procedures 
Chemicals and Antibodies 
The sources of the antibodies used were as follows: mouse monoclonal antibodies 
against tubulin and Flag (Sigma), rabbit polyclonal antibodies against EDD (Novus Biologicals), 
GFP, HA (Santa Cruz Biotechnology), and UVRAG (Sigma). zVAD and TNF were from Cell 
Sciences (Canton, MA).  
 
Immunoprecipitation 
293T cells were transfected with indicated overexpression constructs for 24hrs. Cells 
were harvested with lysis buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 1mM EDTA, 1% NP-40   124 
and protease inhibitor cocktail), and incubated overnight with Flag beads (Sigma). After 
washing four times with the lysis buffer, protein sample buffer was added to the beads to 
denature the immunoprecipitated proteins. After harvesting the cells, all experiments were 
performed at 4C or on ice.  
 
Ni
2+ Pulldown assay 
293T cells were transfected with indicated constructs including 6X His-tagged ubiquitin 
for 24hrs. Cells were harvested with denaturing lysis buffer (10mM Tris-HCl pH 8.0, 100mM 
NaH2PO4, 500mM NaCl, 10% glycerol, 0.1% Triton X-100, 10mM b-mercaptoethanol, 10mM 
imidazole), and incubated for 4hrs with Ni
2+-NTA beads (Qiagen). After washing four times with 
the lysis buffer with 30mM imidazole, the beads were eluted with elution buffer (0.15M Tris-
HCl pH 6.7, 5% SDS, 30% glycerol, 200mM imidazole, 0.72M b-mercaptoethanol). All 
experiments were performed at room temperature. 
   
Cell Viability Assay 
ATP assay was done with CellTiter-Glo Luminescent Cell Viability Assay (Promega). L929 
cells were plated in 96-well plate. After 18-24hrs of treatment, the assay reagent was added to 
each well and the luminescence was measured with the plate reader.  
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Figure A2.1. Immunofluorescence localization of Vps34 (A) and phosphorylated Vps34 (B) in 
asynchronized HeLa cells  
HeLa cells were fixed and then subjected to immunostaining. Cells were double-labeled with 
anti-Vps34 or affinity-purified phosphorylated Vps34 antibodies and DAPI as nuclear staining. In 
cells of the telophase/cytokinesis phosphorylated Vps34 expression was dramatically reduced 
(Arrows). Bar, 20 μm.   130 
 
 
Figure A2.2. The effects of p150 and Cdk5 expression on T159 phosphorylation and lipid 
kinase activity of Vps34  
293T cells were transfected with indicated expression vectors. The cell lysates were subject to 
western blotting using indicated antibodies. The Vps34 lipid kinase activity in the immune 
complex isolated using anti-Flag antibody was measured in the presence of γ-
32P-ATP as 
described in the Materials and Methods. Relative ratios of the γ-
32P signal divided by the 
amount of Flag-Vps34 protein as measured by densitometry are indicated. 
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Figure A2.3. Interaction of Beclin1 and Vps34  
(A) A schematic representation of Vps34 and Beclin 1 protein structure. Acc, accessory domain; 
Cata, catalytic domain; CCD, coiled-coil domain. (B) The N-terminal C2 domain of Vps34 
interacts with Beclin 1. The cells were transfected with expression vectors of GFP-Beclin 1 and 
full length or truncated fragments of flag-tagged Vps34. Twenty-two hrs after the transfection, 
the cell lysates were immunoprecipitated using anti-flag followed by western blotting with anti-
GFP and flag antibodies. (C) The CCD of Beclin 1 is required for binding Vps34. The cells were 
transfected with expression vectors of flag-tagged full length or truncated fragments of Beclin 1 
together with that of HA-Vps34; 22 hrs after the transfection, the cell lysates were 
immunoprecipitated using anti-flag followed by western blotting with anti-HA and anti-flag 
antibodies. 